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O cancro da bexiga (BC) apresenta uma das maiores taxas de recorrência 
entre os tumoures sólidos e é a segunda causa de morte, relativamente a 
doenças do trato geniturinário. A introdução de modelos moleculares para um 
melhor prognóstico e desenvolvimento de terapias dirigidas efetivas, continua 
a ser um aspeto desafiador devido à significativa heterogeneidade molecular 
inter e intratumoral. No entanto, a CD44, uma proteína de membrana 
fortemente O-glicosilada e envolvida nas interações célula-célula, adesão 
celular e migração, parece desempenhar um papel crítico na progressão e 
disseminação do cancro da bexiga, abrindo portas para potenciais terapêuticas 
dirigidas. No entanto, o gene que codifica esta proteína geralmente sofre 
splicing alterativo, o que resulta em diversas isoformas funcionalmente 
distintas, de pesos moleculares variáveis e com vários locais de glicosilação. 
No entanto, a natureza dessas isoformas no contexto do cancro da bexiga 
ainda não está bem esclarecida. Com base nestas ideias, este trabalho tem 
como objetivo determinar as isoformas da CD44 mais clinicamente relevantes 
e com potencial de direcionar para clones mais agressivos. É dado particular 
ênfase à identificação de O-glicanos associados ao cancro, que visam 
aumentar o entendimento molecular para o desenho de ligandos altamente 
específicos. Consequentemente observou-se que a CD44 está aumentada na 
urina de doentes com cancro de bexiga, comparativamente com urinas 
controlo de indivíduos saudáveis. Esse efeito é mais pronunciado em estadios 
avançados da doença, particularmente após a invasão muscular, o mesmo se 
verifica com expressão da CD44 nos tumores de bexiga. 
Além disso, uma abordagem direcionada por RT-PCR demonstrou que o 
modelo celular de tumores superficiais de cancro da bexiga, a linha celular 
5637 e os tumores de bexiga não invasivos sobre-expressam isoformas da 
CD44 de alto peso molecular (CD44v3-10high, CD44v8-10high, CD44slow). Por 
outro lado, as linhas celulares T24 e HT1376 derivadas de tumores musculo-
invasivos e estes mesmos tumores sobre-expressam predominantemente 
CD44s, uma isoforma de menor peso molecular (CD44v3-10low, CD44v8-10low, 
CD44shigh). Além disso, os clones quimiorresistentes das células T24, tratadas 
com cisplatina, também sobre-expressam CD44s. Da mesma forma, os 
tumores invasores apresentaram um fenótipo semelhante, apoiando a 
associação da CD44 com fenótipos mais agressivos. Os estudos de glicómica 
e glicoproteómica envolvendo a linha celular T24 demonstraram ainda a 
expressão de CD44 glicosilado com antigénios sialil-Tn (CD44-STn) e di-sialil-
T (dST), anteriormente associados a um pior prognóstico. Em paralelo, ensaios 
de imuno-histoquímica e de ligação de proximidade in situ confirmaram a 
existência de CD44-STn e CD44-dST em tumores musculo-invasivos. 
Em conclusão, CD44s, possivelmente modificada com STn e dST, tem o 
potencial de direcionar selectivamente para células mais agressivas de 
tumores de bexiga e clones quimiorresistentes, estabelecendo assim as bases 
moleculares para o desenho de ligandos. Estudos futuros devem-se concentrar 
em avaliar o impacto funcional da remodelação da CD44 para isoformas de 
menor peso molecular, acompanhando a transição de tumores superficiais 
para invasores. 
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abstract Bladder Cancer (BC) presents one of the highest recurrence rates amongst 
solid tumours, and constitutes the second deadliest disease of the 
genitourinary track. The introduction of molecular models for disease 
management and effective targeted therapeutics remains a challenging aspect 
due to significant inter and intra-tumour molecular heterogeneity. Nevertheless, 
CD44, a heavily O-glycosylated membrane protein involved in cell-cell 
interactions, cell adhesion and migration has been suggested to play a critical 
role in bladder cancer progression and dissemination, holding potential for 
targeted therapeutics. However, the gene encoding for CD44 generally 
undergoes significant alterative splicing, which results in many functionally 
distinct isoforms of variable molecular weights and glycosylation sites. 
Nevertheless, the nature of these isoforms in bladder cancer are yet to be fully 
disclosed. Building on these insights, this work aims to highlight clinically 
relevant CD44 isoforms with potential for targeting more aggressive clones. 
Particular emphasis is also given to the identification of cancer-associated O-
glycans envisaging the molecular rational for designing highly specific cancer 
ligands. Accordingly, it was observed that CD44 is increased in the urine of 
bladder cancer patients in relation to healthy controls. This effect is more 
pronounced for advanced stages of the disease, particularly upon muscle 
invasion, mimicking CD44 expression in bladder tumours.  
Moreover, a targeted approach by RT-PCR demonstrated that superficial 
bladder cancer cell model 5637 and non-invasive bladder tumours overexpress 
high molecular weight CD44 isoforms (CD44v3-10high, CD44v8-10high, CD44slow 
phenotype). Conversely, T24 and HT1376 cell lines derived from muscle 
invasive tumours and invasive lesions predominantly overexpress lower 
molecular weight isoform CD44s (CD44v3-10low, CD44v8-10low, CD44shigh 
phenotype). In addition, chemoresistant clones from T24 cells challenged with 
cisplatin also overexpressed CD44s. Likewise, bladder tumours from patients 
with invasive tumours presented a similar phenotype, supporting CD44s 
association with more aggressive phenotypes. Glycomics and glycoproteomics 
studies involving T24 cell line further demonstrated the expression of CD44 
glycosylated with sialyl-Tn (CD44-STn) and di-sialyl-T (dST) antigens, 
previously associated with poor prognosis. In parallel, immunohistochemistry 
and in situ proximity ligation assays confirmed the existence of CD44-STn and 
CD44-dST in muscle invasive tumours.  
In conclusion, CD44s, possibly modified with cancer-associated STn and dST 
glycans, holds potential to selectively target more aggressive bladder cancer 
lesions and chemoresistant clones, setting the molecular rational for ligands 
design. Future studies should now focus on disclosing the functional impact of 
CD44 remodelling towards lower molecular weight isoforms, accompanying 
transition from superficial to invasive lesions. 
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1. Introduction 
 
1.1. Bladder cancer 
 
1.1.1. Epidemiology 
 
Bladder cancer (BC) is the most common malignancy of the urinary tract, the 
seventh most common cancer in men, and the seventeenth in women (1). Also, it is the 
ninth most common cancer worldwide, with 429,000 new cases and 165,000 deaths in 
2012 (2). In Portugal, BC is the eighth most common cancer, with 1829 new estimated 
cases and 900 deaths in 2010 (3). The disease is three times more iterated in men than in 
women and its incidence increases with age, reaching a peak between 50 and 70 years 
(4). Moreover, at diagnosis, women present more advanced stages of the disease and 
have less favourable prognosis (5). 
Environmental risk factors have a significant role in BC initiation. Chemical or 
environmental exposures and chronic inflammation are well known risk factors for the 
development of BC and may lead to genetic and molecular changes (6). Critical 
exposures include aromatic amines, aniline dyes, nitrites and nitrates, acrolein, coal, and 
arsenic. Other casual factors include Schistosoma spp (Schistosoma haematobium) 
infection, and pelvic irradiation (7). However, tobacco smoke is the predominant risk factor 
associated with BC, accounting for 50% of BC cases (1). Genetic predisposition also has 
a significant influence on BC development, especially on the susceptibility to other risk 
factors (8). 
Haematuria is the most frequent BC symptom, occurring in approximately 80% of 
patients. Other symptoms include urgency and dysuria, or, in more advanced tumours, 
pelvic pain, and symptoms related to urinary tract obstruction (1). 
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1.1.2. Pathophysiology and disease progression 
 
Urothelial cancers arise from two distinct but overlapping pathways: papillary and 
non-papillary. Approximately, 80% to 85% of urothelial cancers are papillary lesions, 
stemming from hyperplastic epithelium or minimal dysplasia of a preneoplastic clone. The 
continuous growth of this clone results in the development of low-grade superficial 
papillary tumours that present loss of heterozygosity of chromosome 9, frequent mutations 
in the Fibroblast Growth Factor 3 (FGFR3), Harvey rat sarcoma viral oncogene homolog 
(HRAS) and phosphatidylinositol 3-kinase (PI3KCA) genes (9). Non-papillary and invasive 
tumours are thought to arise from severe dysplasia or carcinoma in situ (CIS). In a non-
papillary pathway, cells from the initial hyperplasia develop genetic instability with frequent 
loss of tumour suppressor genes, such as Retinoblastoma (RB) and p53 (10,11). 
Interestingly, most muscle-invasive lesions emerge without a prior history of disease 
(primary invasive bladder cancer) (12,13). 
Urothelial carcinoma (transitional cell carcinoma or TCC), squamous cell 
carcinoma, and adenocarcinoma comprise the three main bladder cancerous lesions, with 
TCC accounting for approximately 90% of cases (14,15). At diagnosis, approximately 75% 
of patients present superficial lesions and low grade tumours, (stages Ta, T1, or tumours 
in situ [Tis]), 10% of which progress to recurrent muscle-invasive and metastatic disease 
(Figure 1) (12,13). Consequently, non-muscle invasive bladder cancer (NMIBC) is a 
chronic disease with varying oncologic outcomes requiring frequent follow-up and 
repeated treatments, making the cost per patient (from diagnosis to death) one of the 
highest of all cancers (16,17). 
 
Figure 3 Schematic representation of bladder cancer 
staging and grading (18). The stage of the primary 
tumour (T) is based on the extent of penetration or 
invasion into the bladder wall.Tis, Tumour in situ: ‘‘flat 
tumour’’; Ta, Non-invasive papillary carcinoma; T1, 
Tumour invades subepithelial connective tissue; T2, 
Tumour invades muscle; T2a, Tumour invades superficial 
muscle (inner half); T2b, Tumour invades deep muscle 
(outer half); T3, Tumour invades perivesical tissue; T4, 
Tumour invades any of the following: prostate, uterus, 
vagina, pelvic or abdominal wall. Regarding tumour 
grading, bladder lesions can be classified as urothelial 
papilloma (a benign lesion), papillary urothelial neoplasm of low malignant potential (PUNLMP), low-grade papillary 
urothelial carcinoma and high-grade papillary urothelial carcinoma. 
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1.1.2.1. Diagnosis and therapeutics of bladder cancer 
 
The most common clinical presentation of BC is asymptomatic hematuria, which 
prompts evaluation with cystoscopy, renal function testing, and upper urinary tract imaging 
in adults over 35 years with irritative voiding symptoms, and risk factors for bladder cancer 
(1,14). Moreover, tremendous efforts have been put in the development of biomarker 
panels for early diagnosis, with promising results regarding several glycans, lectins and 
proteoglycans (18) 
The standard therapy for low-grade NMIBC is transurethral resection (TUR) of the 
tumour, allowing staging and primary treatment design. Further management is based 
upon risk factors, stage, grade, multimodality and recurrence history. Accordingly, a dose 
of perioperative chemotherapy can be used to reduce the risk of recurrence, and adjuvant 
chemotherapy is reserved for patients with multiple or multifocal recurrence. Moreover, 
there are subgroups of high-risk NMIBC patients which endure TUR and perioperative 
chemotherapy, followed by intravesical Bacillus Calmette-Guérin (BCG) therapy (19). Of 
note, intravesical BCG therapy is highly effective in comparison to chemotherapy alone 
(20). However, only two thirds of patients respond to BCG and one third of those 
responders will have recurrent disease (21), urging biomarkers able to predict therapy 
response and stratify patients who benefit the most from treatment. 
Upon tumour invasion of the bladder wall (T2), perivesical tissue (T3), or adjacent 
pelvic organs (T4), endoscopic tumour resection and intravesical therapy become 
insufficient and the standard approach is radical cystectomy with pelvic lymphadenectomy 
and adjuvant or neoadjuvant chemotherapy (cisplatin-based combinations: methotrexate, 
vinblastine, cisplatin and doxorubicin - MVAC, or gemcitabine and cisplatin - GC) (14,22). 
Radical cystectomy may achieve a good local control; however, the relapse rate after 
radical cystectomy is as high as 50%, depending on the pathological stage of the primary 
tumour and the presence of loco-regional or distant metastasis (23). Importantly, the 
introduction of cisplatin-based chemotherapy in recent therapeutic schemes has allowed 
improving survival in comparison to cystectomy alone (24). Moreover, cisplatin-based 
chemotherapy results in nearly 15.2 and 14.0 months overall survival for MVAC and GC, 
respectively, compared to monotherapy and other combinations (25). Data from 
retrospective surgical series show that despite the early use of such aggressive 
approaches, many patients with muscle invasive bladder cancer (MIBC) still have high risk 
of recurrence and death from bladder cancer. The majority of recurrences occur within 3 
years, with approximately 75% of patients already presenting distant metastasis (23). 
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Currently, there is a lack of specific biomarkers for targeting aggressive cell 
phenotypes. Additionally, the high molecular heterogeneity of MIBC is responsible for 
significant variations in disease course, as well as elevated recurrence and progression 
rates, hampering patient stratification regarding treatment response (BCG, 
chemotherapy). As such, to improve current clinical practices, bladder tumours of different 
stages have been widely screened for disease-specific glycosylation biomarkers capable 
of improving diagnose, surveillance, prognosis and offer novel therapeutic options. 
 Lately, there have been some evidences linking the expression of CD44 and the 
isolation of bladder tumour-initiating cells. Chan K, et al., (26) isolated tumour-initiating 
cells (T-ICs) from bladder tumours based on the expression of basal cell markers. 
Particularly, CD44+, CK5+, CK20- (T-ICs) cells could be successively transplanted up to 3 
passages to induce tumour formation in vivo, with the tumours retaining the heterogeneity 
of the primary tumour. CD44+, CK5+, CK20- cells could yield either CD44+, CK5+, CK20- or 
CD44-, CK5-, CK20+ (differentiated progeny) tumours. In contrast to T-ICs, the 
differentiated subpopulation could not be successively transplanted, revealing its limited 
self-renewal and/or proliferative capacities. Later, the same authors stratified bladder 
cancer into subtypes regarding cellular differentiation states based on keratin profiles, 
demonstrating that undifferentiated (basal-like) cells were CD44+ (27). These results 
suggest that CD44 expression characterizes undifferentiated BC cells with sustained self-
renewal, thereby being a cancer stem cell (CSC) marker. 
 
  
1.2. Glycoprotein CD44: potential biomarker of poor 
prognosis in bladder cancer 
 
1.2.1. Molecular structure and biological role 
 
The CD44 antigen is a multifunctional and densely glycosylated transmembrane 
glycoprotein that together with selectins, integrins and cadherins composes the cell 
adhesion molecules (CAMs) family, mediating cell-matrix and cell-cell interactions, cell 
adhesion, migration, and tissue integrity (28,29). 
The CD44 gene comprises 19 exons (1-19), of which only exons 1-5 and 15-19 
are conserved, while the remaining 9 exons (6-14 exons also known as v2-v10) undergo 
alternative splicing (Figure 2). Particularly, the canonical CD44v2-v10 isoform contains all 
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variable exons (v2-v10) without the conserved exon 18, constituting the bulkiest CD44 
isoform (250 kDa) (30,31). In turn, the standard CD44 (CD44s or CD44h) constitutes a 
much shorter CD44 isoform by losing all variable exons and exon 18, yielding an 85 kDa 
protein (32,33) (Figure 2). Moreover, the CD44v3-v10 isoform loses both v2 and 18 
exons, being primarily found in keratinocytes, while the isoform CD44v8-v10 (CD44E) 
loses both v2-v7 and 18 exons and is preferentially expressed in epithelial cells (34). In 
addition, CD44v10 isoform loses all variable exons except v10, as well as the constitutive 
exon 18. Finally, the CD44st isoform, also known as short-tail CD44, loses all variable 
exons and exon 19. More recently, two more CD44 isoforms, namely CD44 NCBI 
Transcript 7 and CD44RC were described in UniProt and NCBI databases (35,36). 
Particularly, CD44 NCBI transcript 7 loses all variable exons, exon 15 and exon 18, while 
CD44RC is solely constituted by the first four conserved exons (Figure 2) (35,36). Of note, 
CD44 has several predicted isoforms that remain to be described in research models or 
humans, urging more in-depth studies regarding these markers. 
Moreover, CD44 presents multiple post-translational modification sites, with at 
least five N-glycosylation sites in its ectodomain and several potential O-glycosylation 
sites in the membrane proximal extracellular region (37,38); thereby affecting its ligand 
binding characteristics, modulating its functions and further diversifying its structure (39). 
CD44 can also be considered a “part-time” proteoglycan, since some of its alternative 
splicing variants present glycosaminoglycan (GAG)-initiation sites (40). Further 
modifications can occur through tyrosine sulphation (41).  
Hyaluronic acid (HA), an important component of the extracellular matrix (ECM), is 
the most common, but not the only, ligand of CD44. HA is a linear polymeric GAG and 
there are at least three sites for its binding on the CD44 molecule, one of which is the 
“link” domain encoded by exon 2 (42), and the other two overlap in the region encoded by 
exon 5 (43). Although all CD44 isoforms contain HA recognition sites, not all cells 
expressing CD44 constitutively bind the HA ligand. Cells can express CD44 in an active, 
an inducible, or an inactive state with respect to HA binding. The differences in the HA 
binding state of CD44 are cell specific and have been related to post-translational 
modification patterns (44). This interaction between CD44 and HA has been reported in 
chondrocytes, being an important process to direct the assembly of pericellular matrices 
(45) and chondrosarcoma cell lines adhesion (46). In addition, cells undergoing repair 
appear to upregulate both CD44 and HA. Mukesh Jain, et al., demonstrated that CD44 
and HA are expressed in minimal amounts on smooth muscle cells in normal arteries, in 
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opposition to injured arteries where the expression of these two molecules was much 
higher (47).  
Several lymphocyte functions also appear to be CD44-dependent. Namely, there 
is an increase in cell surface levels of CD44 in activated T-cells (48). Additionally, CD44 
expression seems to mediate the adhesion of lymphocytes to vascular endothelial cells 
via its binding to HA, and this interaction seems to be associated to T-cell extravasation 
into inflammation sites in mice (49) and humans (50). The homing of lymphocytes to 
inflammatory sites through CD44–HA binding is enhanced by the induction of HA 
synthesis in vascular endothelium by the proinflammatory cytokines tumour necrosis 
factor α (TNF-α) and interleukin 1β (IL-1β) (51). Accordingly, the presence of CD44 
splicing variants appears to be obligatory for the migration and function of Langerhans 
and dendritic cells from peripheral organs to lymph nodes for antigen presentation (52). 
As it was previously discussed CD44 presents different ligands beside hyaluronic acid, 
such as osteopontin.  Osteopontin (OPN) is highly expressed in bone. It is also known as, 
early T-lymphocyte activation (ETA-I) (53). This protein has revealed to be associated with 
regulation of immune cells, namely, promoting cell-mediated immune responses, playing a 
role in chronic inflammatory diseases, infiltration of macrophages during inflammation and 
induction of pro-inflammatory cytokines expression (54,55). 
As it was described above, CD44 is involved in cell-cell and cell-matrix 
interactions, proliferation, migration and adhesion, which are directly involved in tumour 
progression and metastasis (56,57). As such, the clinical relevance of CD44 will be 
discussed in the next sections. 
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Figure 2 Human CD44 structure and examples of alternatively spliced mRNA transcripts. Blue filled boxes represent 
constitutive exons, white filled boxes represent alternative exons. The blue line represents the alternative region that is 
missing in each CD44 isoform. The exon box width is not proportional to the bp number. Exon 18, filled black, is not coding 
and contains early 3′UTR. Its inclusion gives rise to a short cytoplasmic tail mRNA that translates into CD44st. Seventy 
amino acids of cytoplasmic tail are encoded by exon 19. Cytoplasmic tail of CD44 contains intracellular signalling motifs and 
mediates interaction with cytoskeleton. Variable region of CD44 is a site of heavy O-glycosylation. The globular amino 
terminal domain of CD44 contains 3 disulphide bonds and two hyaluronic binding motifs.  
 
 
1.2.2. Clinical relevance in solid tumours 
 
The expression of CD44 isoforms and its binding to HA is associated with tumour 
growth and development (58). Moreover, some studies describe unusual CD44 transcripts 
not found in the corresponding normal tissues (30,59). Furthermore, it was demonstrated 
that in vivo tumour formation by human lymphoma Namalwa cells, stably transfected with 
CD44s, can be suppressed by a soluble human CD44s-immunoglobulin fusion protein 
disrupting the interaction between CD44s and its physiologic ligands. Moreover, no 
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tumour growth was detected even 100 days after the initial tumour cell injection. These 
results may provide new insides for tumour growth control in vivo (60). Both CD44s and its 
isoform CD44v10 expression are highly associated with malignant melanoma, and 
CD44v10 appears to facilitate local invasion. Accordingly, treatment of B16F10-bearing 
C57BL/6 mice either with a CD44s-/ CD44v10-specific antibody, or with receptor globulins 
(Rg) containing the extracellular part of CD44s or CD44v10 linked to the constant region 
of the immunoglobulin kappa light chain resulted in a reduction of lung metastasis. 
However, only CD44 Rgs prevented spread and settlement of melanoma cells in distant 
organs. These findings confirm the involvement of both CD44s and CD44v10 in 
melanoma progression, and is suggestive for the use of Rgs as therapeutic reagents (61). 
A similar study in malignant melanoma also demonstrated that CD44 blockage by specific 
antibodies inhibits tumour growth and metastisation in vivo by disrupting CD44-HA 
interactions (62). In line with these findings, tumour cell lines with high levels of CD44 
protein were shown to be capable of forming more aggressive tumours in animal models 
(63,64).  
CD44 also seems to be involved in lymphocytes preservation. Particularly, CD44 
appears to inhibit DNA fragmentation and apoptosis of immature lymphocytes and 
peripheral T lymphocytes induced by anti-CD3 monoclonal antibodies (MoAbs) and 
glucocorticoid hormones (GCH), therefore modulating T-cell survival (65). In addition, 
CD44 provided resistance to anti-integrin antibody induced apoptosis of colon carcinoma 
cell lines, demonstrating the possibility of this molecule involvement in poor prognosis of 
colon carcinoma and metastasis development (66). 
 Furthermore, osteopontin and CD44 intereractions have been associated to 
tumour dissemination and metastization in brain tumours (67). Through the interaction 
with integrin receptors on macrophages and CD44, OPN seems to promote a delayed 
immune system response, inducing cellular immunity and an anti-oxidant effect preventing 
cell damage (67). Moreover, tumour dissemination is associated to neovascularization. 
CD44 isoforms and integrin aVβ3 are highly associated with angiogenesis process in 
tumours. Expression of CD44, osteopontin and integrin aVβ3 have been demonstrated to 
be involved in endothelial cell migration by vascular permeability factor/vascular 
endothelial growth factor (68,69).   
 
1.2.3. CD44 in bladder cancer 
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There have been some studies relating the expression of CD44 proteins and 
several biologic and clinical roles in bladder cancer. Kuncová J, et al. (70) evaluated the 
expression of CD44s and CD44v6 in 5637 and HT1197 BC cell lines, reporting that 
expression of both isoforms was dependent on the differentiation state of cells. 
Particularly, undifferentiated 5637 cells presented a more regular positive staining for 
CD44 proteins, while the more differentiated HT1197 displayed variations in CD44 
staining. Also, CD44 proteins expression was correlated with higher proliferative activity 
and stem-like phenotypes of HT1197 and 5637, as well as with cellular atypia in HT1197. 
Moreover, it was suggested that variations in CD44 expression might be connected to the 
derangement of differentiation in tumour cells, manifested by prominent cytological atypia 
in high-grade tumours. 
It is known that CSCs can be isolated from several solid tumours, such as breast 
(71) and brain tumours (72); however the lack of bladder cancer stem (initial) cells 
(BCICs) markers has hampered the same progress in bladder cancer. Yang Y, et al. (73) 
reported that BCICs might be among the epithelial membrane antigen (EMA)- CD44v6+ 
subset isolated from bladder tumours by magnetic cell sorting, since both EMA- cells and 
CD44v6+ cells possess the ability for colony-forming, self-renewal and proliferation. 
Importantly, these cells are usually located in the basal layer of normal urothelium, the 
potential location of BCICs, and would infiltrate from basal layer towards superficial layer 
in tumourous urothelium. 
Inflammation events in normal and CSCs might be associated to prostaglandin E2 
(PGE2) signalling (74), which has been reported to regulate hematopoietic stem cells 
homeostasis (75). Cyclooxygenase-2 (COX-2), the PGE2-generating enzyme, is 
determinant to inflammation-related carcinogenesis (76) and COX inhibitors present 
antitumour activity (77). Having the above in consideration, Thanan R, et al. (78) 
suggested that COX-2 may play an important role in tumour initiation, regulation of stem 
cell proliferation and differentiation in inflammation-related bladder cancer carcinogenesis. 
Particularly, S. haematobium-induced BC was correlated with stemness marker Oct3/4 
expression, while BC without associated infection correlates with CD44v6 expression. 
Moreover, the expression of Oct 3/4 and CD44v6 was associated with nuclear localization 
of COX-2, suggesting that inflammation could mediate stem cell proliferation and 
differentiation in bladder cancer. 
In a clinical approach, CD44v9 was reported to be an important prognostic 
biomarker for disease progression and cancer-specific death in MIBC and high-grade 
NMIBC (79). Its localization in invasion fronts demonstrated the clinical value of CD44v9 
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expression, which could be used as stratification marker to select patients who might 
progress to muscle-invasive bladder cancer. In turn, it was demonstrated that CD44s and 
CD44v6 correlate with tumour stage and grade (80). Particularly, low-grade papillary TCC 
exhibited staining of basal layer cells, with a decreasing intensity of staining towards the 
urothelium surface, while high-grade TCC displayed strong staining of CD44s and 
CD44v6 throughout the entire neoplastic urothelium. Tumour grade and depth of invasion 
also correlated with positive staining of CD44s and CD44v6, confirming the diagnostic and 
prognostic value of both markers. It was also evidenced that CD44v6 is an indicator of 
metastatic potential with an increased expression in higher stages and in tumours with 
infiltrating borders (80). Another study also associates CD44s expression with higher 
grade, stage, and density of tumour infiltrating lymphocytes, as well as shorter overall 
survival, while CD44v6 expression was associated with better prognosis, lower grade and 
increased overall survival (81). Contrastingly, another study reported that the loss of 
CD44v6 expression is an independent adverse predictor of recurrence and overall 
survival, further suggesting that routine evaluation of CD44v6 could be important in 
identifying high-risk patients which would benefit from more aggressive therapeutic 
approaches. Also it was hypothesised that CD44v6 expression could be a much better 
predictor of recurrence than BC grade (82).  
The knowledge regarding the clinical significance of CD44 in BC is still scares, 
which allied to conflicting reports has hampered the true development of targeted 
therapies involving this marker. These discrepancies can be explained by the lack of 
standard immunohistochemical assays, the use of antibodies with different specificities, 
and differences in the clinicopathological status of bladder tumours used in the different 
studies. Therefore, integrative and standardized studies are necessary to elucidate the 
role of CD44 in BC as it holds an important biological and clinical value and may serve as 
therapeutic target. Moreover, the structural complexity of this glycoprotein, including the 
coexistence of different splicing variants in the same tumour (83) and significant 
heterogeneity in glycosylation patterns (39) also may explain the existence of conflicting 
data. Therefore, it is crucial to determine the nature of the splicing variants expressed by 
bladder tumour of different histopathological natures, as well as their biological and clinical 
significances. Moreover, since CD44 is a highly O-glycosylated protein, exploiting its O-
glycosylation patterns may allow narrowing down its isoforms to clinically relevant 
glycospecies capable of improve BC management (detection, prognosis, follow-up, and 
therapy selection).  
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1.3. Protein glycosylation and cancer 
 
1.3.1. Patterns of glycosylation 
 
Protein glycosylation is the most frequent post-translational modification (PTM) of 
membrane-bound and secreted proteins. This non-templated process involves the highly 
coordinated action of several glycosyltransferases, glycosidases and nucleotide sugar 
transporters in the endoplasmic reticulum (ER) and Golgi apparatus (GA) to generate 
carbohydrate-associated proteins. Glycosylation increases proteome complexity due to 
the diversity in sugar compositions, glycosidic linkages (N- , O- and C-linked glycosylation, 
glypiation (GPI anchor attachment) and phosphoglycosylation), chain length and 
substitution patterns (84–88). Given its structural diversity, glycans are important 
mediators of a plethora of biological events, such as cell-cell adhesion, cell differentiation, 
migration, signalling transduction, immune recognition, host-pathogen interactions, protein 
folding, traffic and stability (89–91). 
Two main classes of glycans can be found at the cell surface, namely N- and O-
glycans (Figure 3). Although glycosylation has been characterized as a post-translational 
modification, N-glycosylation often occurs during the translation and transport of proteins 
into the ER, promoting the proper folding of newly synthesized polypeptides. Precursor N-
glycan synthesis begins on the cytosolic face of the ER and is further elongated after the 
initial structure is flipped into the ER lumen (91). During N-glycan synthesis, a 14-
sacharide “core” unit (Glc3Man9GlcNAc2-) is transferred by oligosaccharide transferase 
(OSTase) to asparagine (Asn) residues in an Asn-X-Ser/Thr sequence of the nascent 
protein, with X being any amino acid except proline. The diversification of the glycans 
occurs in the GA to yield either partially unprocessed oligomannose antenna or, more 
frequently, complex or hybrid type structures (92). Mature N-glycans often yield highly 
relevant terminal structures, such as Lewis (Le) blood group related antigens and ABO(H) 
blood group determinants (93). Further glycome complexity is added by sugar 
phosphorylation, O-acetylation of sialic acids, and O-sulfation of galactose and N-
acetylgalactosamines (94). 
N-glycosylation does not prevent O-glycosylation from happening, as O-
glycosylation commonly takes place on glycoproteins previously N-glycosylated in the ER. 
O-glycosylation occurs post-translationally by covalently α-linking a N-
acetylgalactosamine (GalNAc) moiety to protein serine (Ser) or threonine (Thr) residues 
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by UDPGalNAc-polypeptide N- acetylgalactosaminyl- transferases (ppGalNAc-Ts), 
forming the simplest O-glycan Tn antigen. Subsequently, T antigen (core 1 or Thomsen-
Friedenreich antigen) results from the attachment of a galactose (Gal) to GalNAc by T 
synthase (β1-3 galactosyltransferase or C1GalT-1) (95). Moreover, T antigen can be the 
precursor of several more complex core structures (from core 2 to 8) bearing similar 
terminal structures than mature N-glycans (96). In addition, Tn and T antigens can be 
sialylated by sialyltransferases, forming the sialyl-Tn (STn), sialyl-T (ST) and disialyl-T 
(dST) antigens. Upon formation of the STn antigen, any further processing of the 
oligosaccharide chain stops (97).  
In cancer tissues, glycosylation patterns are profoundly altered, being 
characterized by the expression of highly branched and heavily sialylated/fucosylated 
glycans, alterations in glycan terminal structures, and overexpression of truncated glycans 
(18,98). Glycome alterations at the cell surface derive from the synergism of different 
events that go beyond altered glycosyltransferases and/or glycosidases expression. 
These may include alterations in peptide backbone or nascent glycan structures (99), 
glycosidases or glycosyltransferases activity (100,101), chaperone functions (102), 
glycosyltransferases mislocation in secretory organelles (103), and the bioavailability of 
sugar nucleotide donors and cofactors (104). Importantly, many glycoepitopes constitute 
tumour-associated antigens. Those found at the cell surface are easily accessible to 
antibodies and lectins to selectively target specific tumour cells, while those secreted or 
shed into bodily fluids can be explored for non-invasive cancer diagnosis through 
serological assays. As such, cancer specific alterations to protein glycosylation provide a 
unique opportunity for clinical intervention. 
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Figure 4 Schematic representation of protein-associated glycan structures relevant in bladder cancer (18). The 
figure represents specific N-linked and O-linked glycan structures, as well as terminal Lewis and sialylated Lewis structures 
that have biological significance in bladder cancer. Key enzymes mediating the addition of specific sugars are also shown. 
Protein N-glycan alterations include the β1-6 branching of N-glycans in result of GlcNAcT-V (GnT-V) overexpression, and 
the addition of bisecting GlcNAc branches by GlcNAcT-III (GnT-III) glycosyltransferases. Alterations in O-glycosylation 
pathways are also a common hallmark of malignant transformations of the bladder. Herein, we represent the overexpression 
of simple mucin-type O-glycans and their sialylated counterparts, T, sialyl T (ST), Tn and sialyl Tn (STn) antigens. Altered 
expression of terminal structures is also a common feature of bladder tumours. Namely, the abnormally low or absent 
expression of ABO(H) blood group determinants is frequently found in high grade and invasive disease. Carbohydrate 
terminal Lewis antigens are significantly under-expressed in healthy urothelium when compared to bladder tumours and are 
also highlighted here. Lewis type 1 antigens includes Lewisa (Lea), and sialyl Lewisa (SLea), while the type 2 group includes 
Lewisx (Lex) and sialyl Lewisx (Slex).  
 
1.3.2. Altered glycosylation in bladder cancer 
 
It has been long known that advanced stage bladder tumours present severe 
dysregulations in glycosylation pathways, translated by the loss of terminal ABO blood 
group determinants at the cell-surface of ABH secretor individuals (105,106), over- and/or 
de novo expression of short-chained O-GalNAc glycans (107), Lewis blood group related 
antigens, and their sialylated counterparts (108,109), as well as oversialylation and 
fucosylation of glycan chains (110). Particularly, ABO(H) antigens in the initial biopsy of 
bladder carcinomas is predictive of a much higher chance of subsequent invasion than in 
those tumours in which the ABO(H) antigens are detectable (111). However, a significant 
number of patients whose initial tumours were reported as blood group antigen negative 
failed to develop an invasive tumour (111). It is possible that these conflicting results may, 
at least in part, be explained by differences in methodology, interpretation, or both. These 
antigens are present on normal bladder epithelium but not on some low-grade and early- 
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stage papillary transitional cell carcinomas of the bladder (112). In bladder urothelium the 
most studied change has been the deletion of blood group A antigens from A individuals 
and H antigen from O individuals. Moreover, the loss of activity of the A and B gene-
encoded transferases (112), and ABO(H) gene and/or its promoter hypermethylation (105) 
have been suggested to be amongst the events driving these, explaining the deletion of 
these antigens in bladder tumours. 
The A, B, H antigens have biosynthetic and structural similarities with the Lewis 
antigens, including the type 1 Lewisa and type 2 Lewisx antigens and their sialylated 
counterparts, namely sialyl-Lewis a (SLea) and x (SLex). Several authors have associated 
Lewisa expression patterns with malignant transformations, reporting significantly lower 
expression of this antigen in healthy urothelium when compared to invasive tumours 
(113,114). As such, the expression of Lewisa can be associated with worse bladder 
cancer phenotypes. Moreover, Lewisa antigen expression patterns change at an early 
neoplastic stage, suggesting that Lewisa determination might be useful in the diagnosis of 
very early premalignant changes in the urothelium (115). In addition, the employment of 
Lewisa staining scores allows the sub-classification of histologically identical tumours into 
prognostically different groups, pointing to a relationship between the pathological grade 
and stage of the evaluated tumours and a morphological and functional de-differentiation 
(115). Given this, Lewisa antigen is a valuable functional marker of the malignant potential 
in superficial bladder cancer. In turn, the Lewisx antigen is not expressed in normal 
urothelium, except for occasional umbrella cells, but is demonstrated in most invasive 
tumours, regardless of blood type and secretor status of the individuals studied (106). In 
cancer cells, both SLea and SLex mimic their normal expression on blood cells, allowing 
cancer cell binding to endothelial selectins and extravasation of cancer cells (116). 
Minimal structural alterations in SLe terminal motifs may significantly alter their biological 
behaviour, allowing them to be explored has biomarkers of disease. Namely, a glycan 
epitope that is very similar to the selectin ligand SLex, the sialyl-6-sulfo Lewisx, is 
preferentially expressed in normal epithelial cells compared to cancer cells (117). 
Essentially all genes involved in the synthesis of SLex are predicted to be the same as 
those governing the synthesis of sialyl-6-sulfo Lewisx, except for the genes engaged in its 
sulfation. This finding supports the hypothesis that reduced expression of sialyl-6-sulfo 
Lewisx induces SLex expression in cancers(118). Sialyl-6-sulfo Lewisx antigens are 
expressed in bladder urothelial carcinomas playing divergent roles in its progression, 
since it promotes E-selectin-mediated tumour cell adhesion to vascular endothelial cells, 
which is potentially associated with metastasis, while aiding lymphocyte recruitment to 
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enhance anti-tumour immune responses (119). A structure very similar to SLea termed 
disialyl-Lewisa is preferentially expressed in non-malignant cells, and is useful as a marker 
for tissue injuries occurring in benign diseases (120). The structural difference between 
SLea and disialyl-Lewisa is the presence of one extra sialic acid residue attached to the C-
6 position of βGlcNAc in the carbohydrate structure of the latter glycan epitope. This 
implies that the α-2-6 sialylation of the GlcNAc moiety is impaired in cancer cells 
compared to non-malignant cells. Moreover, this event has been associated with the 
epigenetic silencing of the ST6GalNAcIV gene responsible for the α2-6 sialylation of the 
βGlcNAc moiety in cancer cells (120,121). The sialylated forms of Lewis antigens have 
also been associated with BC malignant potential. Particularly, it has been demonstrated 
that loss/reduction of SLea expression was associated with higher atypia grade (122), 
while SLex has been closely linked to invasive and metastatic potential of primary bladder 
tumours (123). Yet, another study demonstrated no associations between SLex, grade or 
stage in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder (122). 
Notwithstanding, the overall increase in cell-surface sialic acid content was shown to 
reduce the attachment of metastatic tumour cells to the extracellular matrix, possibly 
protecting them from recognition by the alternative pathway of complement activation and 
favouring metastatic spread (124).  
ABO(H) loss may also stem from premature stop in protein O-GalNAc 
glycosylation, ultimately translating in the accumulation of Tn, T and their sialylated 
counterparts STn and ST antigens. In particular, the overexpression of ST6GalNAc-I has 
been found to promote the premature sialylation of the Tn antigen and consequent 
formation of the STn antigen in bladder cancer (125,126). Specifically, the STn antigen is 
absent in the healthy urothelium, while being present in more than 70% of high-grade 
NMIBC and MIBC, denoting a cancer specific nature (125). This posttranslational 
modification of cell surface proteins is mostly expressed in non-proliferative tumour areas, 
known for their high resistance to cytostatic agents currently used to improve the overall 
survival of advanced stage bladder cancer patients (125). Recently, a novel STn-
dependent mechanism for chemotherapeutic resistance of gastric cancer cells to cisplatin 
has been described, in which STn protects cancer cells against chemotherapeutic-
induced cell death by decreasing the interaction of cell surface glycan receptors with 
galectin-3 and increasing its intracellular accumulation (113). The relationship between 
chemoresistance and STn overexpression remains to be fully explored in bladder cancer. 
Furthermore, STn expression is significantly higher in MIBC when compared to NMIBC, 
denoting its association with muscle invasion and poor prognosis (127). Studies in vitro 
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have further demonstrated that this antigen plays an important role in bladder cancer cell 
migration and invasion through mechanisms so far unexplored (125,128). However, 
glycoproteomics studies of bladder cancer cell models highlighted that STn was mainly 
present in integrins and cadherins, further reinforcing a possible role for this glycan in 
adhesion, cell motility and invasion (128). Also, recent work from our group has 
demonstrated the presence of STn in lymph node and distant metastasis, strengthening 
the notion that STn expression may influence cancer cell motility and matastization 
capability (129). Moreover, STn inclusion improved the predictive capacity of a molecular 
model proposed for stratification and prognostication of bladder tumours based on keratin 
(KRT14, 5, and 20) expressions (129). Accordingly, the STn antigen has been associated 
with basal-like phenotypes (KRT14+ and/or KRT5+, KRT20-) facing worst prognosis 
(129). Furthermore, STn-expressing BC cells have shown the ability to induce a 
tolerogenic microenvironment by impairing dendritic cells maturation, allowing cancer cells 
to evade innate and adaptive immune system responses (130). Interestingly, the 
tolerogenic effect of short-chained O-glycans has also been correlated with bladder 
tumour metastasis through a mechanism in which MUC1 carrying core 2 O-glycans 
functions as a molecular shield against NK cells attack, thereby promoting metastization 
(131). In addition, STn expression in bladder cancer tissues has been used in combination 
with other surrogate markers of tumour aggressiveness envisaging patient stratification 
regarding disease stage and therapeutic benefit. Specifically, STn and sialyl-6-T (S6T), an 
STn-related antigen, expression are independent predictive markers of BCG treatment 
response and were found useful in the identification of patients who could benefit more 
from this immunotherapy (132). Moreover, STn was found to be a marker of poor 
prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR pathway evaluation, 
holds potential to improve disease stage stratification (127). 
In turn, several reports associated the presence of Tn and T antigens with 
recurrence and metastization in bladder cancer, suggesting that these antigens may be 
surrogate markers of profound cellular alterations (133,134). Also, there is growing 
evidences linking the overexpression of the sialyl-T antigen and ST3Gal.I, the enzyme 
responsible by T antigen sialylation, with bladder cancer aggressiveness, recurrence 
(135), poor prognosis, and tumour grade (133,136). Moreover, the expression of T antigen 
is significantly associated with higher risk for subsequent recurrences with deep muscle 
invasion and metastatic involvement of regional lymph nodes (133,136,137). The fact that 
these simple glycans are absent, significantly under-expressed or restricted to some cell 
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types in healthy tissues, makes them ideal diagnostic and therapeutic targets for bladder 
cancer therapy (138). 
 
1.3.3. CD44 glycosylation in solid tumours 
 
As previously described, CD44 undergoes extensive post-translational 
modification, including N- and O-linked glycosylation and substitution with high molecular 
weight glycosaminoglycans (139), thereby modulating its biological functions. Particularly, 
Dasgupta et al. demonstrated that CD44s O-linked glycosylation decreased CD44s-
mediated adhesion to hyaluronate (HA), while N-linked glycosylation had minimal 
influence on CD44 function. These findings suggest that O-linked glycosylation may be as 
important as alternative splicing in the regulation of CD44 function and the broad 
spectrum of biological processes attributed to it, including normal development, tumour 
metastases, and lymphocyte function (38). Contrastingly, Bartolazzi et al. showed that 
treatment of a panel of human cell lines which constitutively express CD44 with the 
inhibitor of N-linked glycosylation tunicamycin results in the loss of attachment of these 
cells to HA-coated substrate (140) The authors further demonstrated that treatment of the 
same cells with deoxymannojirimycin, which inhibits the conversion of high mannose 
oligosaccharides to complex N-linked carbohydrates, results in either no change or an 
increase in CD44-mediated adhesion to hyaluronate, suggesting that complex N-linked 
oligosaccharides may not be required or even inhibit CD44-HA interaction. Using human 
melanoma cells stably transfected with CD44 N-linked glycosylation site-specific mutants 
it was shown that integrity of five potential N-linked glycosylation sites within the HA 
recognition domain of CD44 is critical for HA binding. Mutation of any one of these 
potential N-linked glycosylation sites abrogates CD44-mediated melanoma cell 
attachment to HA-coated surfaces, suggesting that all five sites are necessary to maintain 
the HA-recognition domain in the appropriate conformation. They also demonstrated that 
mutation of serine residues, which constitute the four Ser-Gly motifs in the membrane 
proximal domain and provide potential sites for glycosaminoglycan side chain attachment, 
impairs HA binding (140). These observations suggest that the relevance of N-
glycosylation sites for CD44 functions is site specific. Olgun Guvench developed 
molecular dynamics simulations that provide atomic-resolution mechanistic understanding 
of CD44-HA interaction to help bridge gaps between existing experimental binding and 
structural biology data. Findings from these simulations included that Tyr42 may function 
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as a molecular switch that converts the HA-binding site from a low affinity to a high affinity 
state; in the partially disordered form of hyaluronan binding domain (HABD), basic amino 
acids in the C-terminal region can gain sufficient mobility to form direct contacts with 
bound HA to further stabilize binding; and terminal sialic acids on covalently attached N-
glycans can form charge-paired hydrogen bonding interactions with basic amino acids that 
could otherwise bind to HA, thereby blocking HA binding to glycosylated CD44 HABD 
(141). Glycosylation modulates CD44 biological role not only by affecting its interaction 
with ligands. Namely, Hu et al. suggest that the Lewis y antigen, as an important 
component of the molecular structure of CD44, promotes proliferation and inhibits 
apoptosis of ovarian cancer cells, leading to drug resistance via activation of PI3K/AKT 
signalling pathways. Moreover, it is proposed that the Lewis y antigen, as a structural 
component of CD44, integrins a5b1 and avb3, as well as EGFR, play a role in various cell 
adhesion processes that mediate both cell adhesion and drug resistance (142).These 
results suggested that fucosylation of CD44 is related to drug resistance in ovarian 
cancer. Campos et al. uncovered CD44-STn glycoforms in gastric cancer patients serum, 
further validating its expression in gastric cancer tissue, suggesting that aberrantly 
expressed CD44 as potential biomarkers in gastric cancer (143). Particularly, the CD44v6 
expression levels were associated with pre-malignant and malignant lesions of the 
stomach, providing a potential biomarker for gastric mucosa transformation (143). Singh 
et al. also reported the coexpression of oncofetal carbohydrate antigens T and STn on 
CD44 splice variants providing a link between cancer-associated changes in glycosylation 
and CD44 splicing, both of which correlate with increased metastatic potential of colon 
cancer (144). 
Regarding BC, Carrascal et al. reported that STn+-CD44 cancer cells impair 
dendritic cells (DC) maturation and endow DCs with a tolerogenic function, limiting their 
capacity to trigger protective anti-tumour T cell responses, suggesting that STn antigens 
and, in particular, STn+ glycoproteins, such as CD44, are potential targets for 
circumventing tumour-induced tolerogenic mechanisms (145). More recently, 
glycoproteomic analyses of advanced bladder tumours based on enzymatic treatments, 
Vicia villosa lectin-affinity chromatography enrichment and nanoLC-ESI-MS/MS analysis 
resulted in the identification of several key cancer-associated glycoproteins carrying 
altered glycosylation, including STn+-CD44 (146). These observations suggest that 
exploring CD44 glycosylation may improve its biomarker potential. Nevertheless, the 
comprehensive glycomics mapping of CD44, including N- and O-glycan patterns, in 
bladder cancer as yet to be performed. 
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2. Aims and Scopes 
 
Bladder Cancer presents one of the highest recurrence rates amongst solid 
tumours, and constitutes the second deadliest disease of the genitourinary track. 
Moreover, the only therapeutic approach for managing advanced patients are cisplatin-
based regimens that often fail to prevent disease relapse and dissemination. The high 
molecular heterogeneity presented by advanced bladder tumours and the lack of specific 
biomarkers for targeting more aggressive cancer cells remain challenging topics in 
bladder cancer management.  
According to the current state-of-the art, CD44 presents an opportunity to address 
more aggressive bladder cancer cells and consequently improve these patients 
management. However, the gene encoding for CD44 generally undergoes significant 
alterative splicing, which results in many functionally distinct isoforms of variable 
molecular weights and glycosylation sites. Nevertheless, at the moment there are no 
consensus regarding the nature of CD44 isoforms associated to muscle invasion, which 
would be crucial for designing targeted therapeutics. 
Having as starting point preliminary associations between increased CD44 levels 
in urine of cancer patients with more aggressive forms of the disease (Appendix 1), the 
first part of this work will be devoted to confirming these observations. The second part of 
the work will focus in disclosing the nature of CD44 isoforms associated with muscle 
invasion and ultimately chemoresistance using molecular models and patient samples, 
envisaging the molecular rationale for intervention. Emphasis will also be set on CD44 O-
glycosylation patterns with the objective of narrowing down the isoforms to clinical 
relevant species. 
Based on these observations, this work comprehends the following specific aims: 
 
i. Identification of clinically relevant CD44 isoforms for targeted therapeutics; 
ii. O-glycome characterization of CD44 isoforms envisaging highly cancer-specific 
target; 
iii. Analysis of CD44 isoform expression in context of chemotherapy 
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3. Material and methods 
 
3.1. Patient and sampling 
 
Between 2010 and 2011, thirty-one first void urine samples without visible signs of 
haematuria were prospectively collected before surgery of bladder cancer male patients 
with mean age of 70 (range, 45–89) years, attending the Portuguese Institute of Oncology 
of Porto (IPO-Porto; Portugal). Only patients that had not been previously submitted to 
neoadjuvant therapy were included. Corresponding formalin-fixed paraffin embedded 
(FFPE) tumours were also obtained for this study. Based on the World Health 
Organization urothelial carcinoma grading and staging criteria, three different groups were 
considered in this study, namely low-grade (n=15) and high grade (n=9) non-muscle-
invasive bladder tumours (NMIBC) and muscle-invasive (n=7) tumours (MIBC). An 
additional 15 urines were obtained from healthy control male volunteers, mean age of 68 
(range 41-82) years. A representative set spanning all stages of disease was also used 
for protein extraction. This included 3 Ta, 3 T1 and 3 MIBC tumours. Furthermore, a 
subset of 10 patients treated with neoadjuvant chemotherapy were included. A total of 20 
formalin-fixed paraffin-embedded (FFPE) tissues sections were analysed, 10 from prior 
chemotherapy transurethral resections (TUR) and 10 from post-chemotherapy 
cystectomies. All procedures were performed under the approval of the institution ethics 
committee and upon patients’ informed consent. All clinicopathological information was 
obtained from patients’ clinical records. 
 
3.2. Cell lines and cell culture conditions 
 
The T24 (grade III), HT1376 (grade III) and 5637 (grade II) bladder cancer cell 
lines used in this work were acquired from DSMZ (Düsseldorf, Germany) and recently 
characterized from the genetic standpoint by our group (147). Accordingly, the T24 cell 
line is representative of the FGFR3/CCND1 pathway, presenting a mutated HRAS and 
overexpression of CCND1. The HT1376 and 5637 cell lines correspond to the E2F3/RB1 
pathway with loss of one copy of RB1 and mutation of the remaining copy. Additionally, 
HT1376 cells exhibit deletion of the Phosphatase and tensin homolog (PTEN) gene and 
 CD44-glycoprofilling: Establishing the molecular basis for targeted therapeutics in bladder cancer| Eliana Soares 
 
28 
 
no alteration of Phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA), which in 
combination with the inactivation of p53, translates into a more invasive and metastatic 
potential. In contrast, the 5637 cell line does not present any loss of PTEN and loses 
PIK3CA gene, which gives it a less-invasive phenotype. 
The cells were cultured in RPMI 1640+GlutaMAXTM-I medium (Gibco, Life 
Technologies) supplemented with 10% heat-inactivated FBS (Gibco, Life Technologies) 
and 1% penicillin-streptomycin (10,000 Units/mL P; 10,000 μg/mL S; Gibco, Life 
Technologies). Cell lines were cultured as a monolayer at 37˚C in a 5% CO2 humidified 
atmosphere, and were routinely subcultured after trypsinization. 
Chemoresistance assays were performed by exposing 1x106 cells of the above-
mentioned cell lines to 3μM cisplatin (Teva Pharma, Portugal) for 72h (ic50 doses 
stablished by Arantes-Rodrigues et al. (148) In parallel, cells were cultured using 
complete media alone and used as controls. Immediately after the incubation periods, 
remaining cells were lysed for protein or RNA extraction. All experiments were performed 
in triplicates and the presented results reflect the average of three independent replicates. 
 
3.3. Isolation of Urine Proteins 
 
Five to forty millilitres of collected urine were centrifuged at 5000xg for 40 min at 4 
°C to remove cells and debris, desalted on Amicon Ultra 10 kDa centrifugal filters (Merck 
KGaA, Darmstadt, Germany) and proteins were resuspended on 50 mM Ammonium 
bicarbonate (pH 7.8, Sigma-Aldrich, St. Louis, MO, EUA). Protein quantification was 
accessed using the DC Protein assay (Bio-Rad, Hercules, CA, USA). 
 
3.4. CD44 analysis by Slot-Blot  
 
Urine proteins (10 g) were slot-blotted on a nitrocellulose membrane (Whatman, 
Protan; pore size 0.45 µm) using the Hybri-slot apparatus (21052-014; Gibco BRL, Life 
Technologies, Waltham, MA, USA). Fetuin from fetal calf serum and deglycosylated 
bovine serum albumin (both purchased at Sigma-Aldrich) were used as positive and 
negative controls, respectively. The amount of protein in the slots was confirmed by 
Ponceau S (Sigma-Aldrich). Nonspecific binding was then blocked with Carbo-Free 
Blocking Solution (SP-5040, Vector Laboratories) for 30 minutes at room temperature. 
 CD44-glycoprofilling: Establishing the molecular basis for targeted therapeutics in bladder cancer| Eliana Soares 
 
29 
 
Samples were screened for CD44 using a recombinant polyclonal antibody (anti-CD44, 
1:150 in PBS; ab157107; Abcam, Cambridge, UK) and a goat anti-rabbit IgG (H+L) 
Secondary Antibody, HRP (Invitrogen, Carlsbad, CA, USA). Reactive bands were 
detected by enhanced chemiluminescence ECL (Amersham Pharmacia Biotech Inc, 
Piscataway, NJ, USA) according to the manufacturer's instructions. Images were recorded 
using X-ray films (Kodak Biomax light Film, Sigma-Aldrich). The films were scanned in 
Molecular Imager Gel Doc XR+ System (Bio-Rad) and analyzed with QuantityOne 
software (v 4.6.3, Bio-Rad). CD44 evaluation was performed in triplicates and the 
presented results reflect the average of three independent measurements. 
 
 
3.5. RNA extraction and mRNA expression analysis 
 
RNA was isolated from FFPE tissue samples using “Absolutely RNA FFPE Kit” 
(Stratagene, La Jolla, CA), according to the vendor’s instructions. Regarding cultured 
cells, total RNA was extracted using TriPure isolation Reagent (Roche Diagnostic GmbH, 
Mannheim, Germany). The RNA quantity and its purity were determined based on the 
A260/A280 using a Nanodrop Lite Spectrophotometer (Fisher Scientific). Only samples 
with ratios between 1.9 and 2.1 were considered for downstream molecular studies. 
Up to 2 mg of total RNA from tissues sections and adherent cells were reverse 
transcribed with random primers, using the “High Capacity cDNA Reverse Transcription 
Kit” (Applied Biosystems, Foster City, CA). The amplification conditions were the 
following: 25C for 10 minutes, 37C for 120 minutes, and reverse transcriptase 
inactivation at 85C for 5minutes. The products were amplified in a StepOne Real-Time 
PCR System (Applied Biosystems) using TaqMan Gene Expression Master Mix, primers, 
and probes provided by Applied Biosystems. TaqMan expression assays were obtained 
from Applied Biosystems CD44: Hs01075864_m1; CD44v3-v10: Hs01081480_m1; CDv8-
v10: Hs01081475_m1; and CD44s: Hs01081473_m1. Schematic representation of PCR 
probes recognition zones is shown on Figure 4. Thermal cycling conditions were: 10 
minutes at 95C followed by 45 cycles of 15 seconds at 95C and 1 minute at 60C. All 
reactions were run in duplicate. GAPDH gene was selected for normalization from a set of 
4 housekeeping genes, ACTB, GAPDH, HPRT and 18S, since it presents higher stability 
among the bladder tumour samples (data not shown). Concerning cultured cells, HPRT 
and B2M were the housekeeping genes selected for normalization. The raw −ΔCt was 
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used to analyze the CD44 expression and therefore used as an estimate of the mRNA 
relative levels. ΔCt stands for the difference between the cycle threshold (Ct) of the 
amplification curve of the target gene and that of the GAPDH or the HPRT/B2M. The 
efficiency of the amplification reaction for each primer-probe is more than 95% (as 
determined by the manufacturer) 
Figure 4 Schematic representation of PCR probes recognition zones. CD44 probe recognizes a sequence in the 
constitutive zone, amplifying any CD44 isoform. CD44v3-v10 is a probe designed to recognize exon-exon boundaries 
containing exon 5 and exon v3., while CD44v8-v10 recognizes exon-exon boundaries containing exon 5 and exon v8. 
CD44s is recognized by exon-exon boundaries containing exon 5 and 15 of the constitutive zone. 
 
 
3.6. CD44 analysis by Western Blot 
 
Proteins were extracted from T24, HT1376 and 5637 bladder whole cell lysates 
with RIPA lysis buffer (50mM Tris [pH=8], 150mM NaCl, 1%NP 40, 0.5% sodium 
deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitor cocktail 
(HaltTM Protease & Phosphatase inhibitor cocktail; Thermo Scientific). Protein 
quantification was done using the DC protein assay kit (Bio Rad) according with the 
manufacturer instructions. Protein samples were separated in reducing SDS/PAGE gels, 
transferred to 0.45 mm nitrocellulose membranes (GE Healthcare Life Sciences, Uppsala, 
Sweden) and blotted for CD44 and β-actin. Prior to blotting protein loads were confirmed 
by Ponceau s (Sigma-Aldrich) staining. The membrane for CD44 and β-actin antigens was 
blocked with Carbo-free Blocking Solution 1X (Vector Laboratories) for 1h at room 
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temperature (RT) and incubated according to Table 1 specifications. After final washing, 
the antibodies were revealed by chemiluminescence using Amersham ECL Prime 
Western Blotting Detection Reagents (GE Healthcare). CD44 expression was normalized 
in relation to -actin. Blots for three independent experiments were performed and the 
presented results reflect the average for three independent replicates.  
 
Table 1 - Specification of primary and secondary antibodies conditions 
 
3.7. Cellular O-glycome analysis by MALDI-TOF-MS 
 
The analysis of the O-glycome in living cells using a chemical O-glycan precursor 
was performed using a modified Cellular O-Glycome Reporter/Amplification (CORA) 
method described by Kudelka et al. (149). Briefly, the Benzyl-α-D-GalNAc (Sigma-Aldrich, 
St. Louis, MO, USA) was acetylated to generate the Benzyl-α-D-GalNAcAc3 by incubation 
with 1:6 pyridine:acetic anhydride for 30 min at 30°C. The compound was purified using 
chloroform-water extraction and dried in a speedvac. Then, the Benzyl-α-D-GalNAcAc3 
was dissolved in 50μL of DMSO and further diluted to 50μM, 150μM and 250 μM in 
complete media with 10% FBS and 1% penicillin-streptomycin. Media with compound was 
administered to approximately 10x106 adherent T24 and HT1317 cells following a 24h, 
48h and 72h incubation period after which conditioned medium was collected. The 
conditioned medium was filtered in 10kDa centrifugal filters (Amicon – Ultra 4, EMD 
Millipore, Burlington, MA, USA) upon 2500×g centrifugation for 1 h at 4ºC and the flow 
through was collected. Subsequently, the Benzyl-α-D-GalNAcAc3-O-glycans was purified 
from the flow through using a Sep-Pak 3 cc C18 cartridge (Waters, Milford, MA, USA) by 
gravity chromatography. The column was equilibrated with 2 × 2 ml acetonitrile, then 4 × 2 
PRIMARY ANTIBODY SECONDARY 
ANTIBODY 
CONDITIONS 
 
Rabbit polyclonal to CD44 (abcam 157107) 
 
Goat anti-Rabbit IgG 
(H+L) Secondary 
antibody, HRP conjugate 
(Invitrogen) 
1º Ab dilution:1:10000, 
1h, RT; 
 
2º Ab dilution 1:60000, 
30’, RT 
   
Anti-Beta-Actin Antibody  Mouse Mono (Sigma-Aldrich) Peroxidase-conjugated 
AffinPure Goat Anti-
Mouse IgG (H+L) 
(Jackson 
ImmunoResearch 
Laboratories, Inc) 
 
1º Ab dilution:1,4µg/µL, 
1h, RT; 
 
2º Ab dilution:1:70000, 
30mins, RT; 
 CD44-glycoprofilling: Establishing the molecular basis for targeted therapeutics in bladder cancer| Eliana Soares 
 
32 
 
ml 0.1% TFA in water. The flow through was added to the column following washing with 
with 4 × 2 ml 0.1% TFA in water. Benzyl-α-D-GalNAcAc3-O-glycans were then eluted with 
2 × 1.5 ml 50% acetonitrile/0.1% TFA in water and dried in a speedvac. The dried Benzyl-
α-D-GalNAcAc3-O-glycans were permethylated using a standard protocol (150) with 500 
μl DMSO/NaOH slurry followed by 200 μl methyl iodide. Samples were shaken for 30 min, 
another 50 μl methyl iodide was added and samples were shaken again for 20 min. The 
permethylated Benzyl-α-D-GalNAcAc3-O-glycans was purified using chloroform-water 
extraction: 1 ml chloroform and 1 ml water were added to supernatant, mixed, and 
centrifuged at 430xg for 2 minutes. Then the aqueous phase is successively removed and 
added for five washing cycles until chloroform is evaporated using a speedvac. 
 Benzyl-α-D-GalNAcAc3-O-glycans were resuspended in 50 μl 50% methanol. 
Then, 0.5 μl matrix (10 mg/ml 2,5-dihydrobenzoic acid, 50% acetonitrile, 0.1% TFA) and 
0.5 μl sample were spotted on target plate, air dried, and analysed by a MALDI-TOF/TOF 
mass spectrometer (4800 Proteomics Analyzer, Applied Biosystems, Europe) in the 
positive ion reflector mode. Peak masses were identified and structures assigned by 
composition and knowledge of glycan biosynthetic pathways, or MS/MS where indicated. 
For the acquisition of tandem mass spectra (MS/MS) of each sample spot, a data 
dependent acquisition method was created to select the 10 most intense peaks, excluding 
those from the matrix. Fragmentation was promoted by collision induced dissociation 
(CID) with air at a pressure of 1.2 e-6 torr in the collision cell. 
 
3.8. Isolation of CD44 isoforms  by immunoprecipitation 
 
Proteins were extracted from whole cells using cell Fractionation buffer (20mM 
HEPES [pH=7.4], 10mM KCl, MgCl2 2mM, EDTA 1mM, EGTA 1mM) containing protease 
and phosphatase inhibitors (HaltTM Protease & Phosphatase inhibitor cocktail; Thermo 
Scientific) and by passing the cell suspension through a 25-gauge needle. Whole cell 
lysates were centrifuged at 720xg for 5 min at 4ºC (cellular debris and nucleus exclusion), 
following a 10000xg centrifugation of the resultant supernatant for 5 minutes at 4ºC 
(mitochondria and zymogen granules exclusion). The subsequent supernatant was then 
ultracentrifuged at 100000xg for 1h at 4ºC to obtain membrane-bound proteins, following 
resuspension by up and down pipetting and passage through a 25-gauge needle. 
Utracentrifugation at 100000xg for 45 min at 4ºC follows. The obtained pellet was 
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resuspended in TBS/0.1% SDS buffer and protein quantified with the DC protein assay kit 
(Bio Rad) according to the manufacturer’s instructions.  
CD44 isoforms were immunoprecipitated from membrane-bound protein extracts 
with polyclonal antibody CD44 (ab157107; Abcam, Cambridge, UK) using the Pierce 
Direct Magnetic IP/CO-IP Kit (Thermo Scientific) according to the supplier’s instructions.  
 
 
3.9. CD44 isoforms identification by nanoLC-MS/MS 
 
For proteomics analysis, CD44 isoforms isolated by immunoprecipitation were 
separated by 4–16% gradient SDS–PAGE under reducing conditions, the bands were 
excised from the gels and proteins reduced with 5 mM DTT (Sigma-Aldrich, Missouri, 
USA) for 40 min at 60˚C, alkylated with 10 mM iodoacetamide (Sigma-Aldrich, Missouri, 
USA) for 45 min in the dark, digested with trypsin (Promega, Wisconsin, USA) in situ, and 
identified by nanoLC-MS/MS. A nanoLC system (Dionex, 3000 Ultimate nano-LC) was 
coupled on-line to a LTQ-Orbitrap XL mass spectrometer (Thermo Scientific, Bremen, 
Germany) equipped with a nano-electrospray ion source (EASY-Spray source; Thermo 
Scientific). Eluent A was aqueous formic acid (0.2%) and eluent B was formic acid (0.2%) 
in acetonitrile. Samples (10 μl) were injected directly into a trapping column (C18 PepMap 
100, 5 μm particle size) and washed with an isocratic flux of 95% eluent A and 5% eluent 
B at a flow rate of 30 μl/min. After 3 min, the flux was redirected to the analytical column 
(EASY-Spray C18 PepMap, 100 Å, 150 mm x 75μm ID and 3 μm particle size) at a flow 
rate of 0.3 μl/min. Column temperature was set at 35º C. Peptide separation occurred 
using a linear gradient of 5–50% eluent B over 90 min., 50–90% eluent B over 5 min. and 
5 min. with 90% eluent B. The mass spectrometer was operated in the positive ion mode, 
with a spray voltage of 1.9 kV and a transfer capillary temperature of 250˚C. Tube lens 
voltage was set to 120 V. MS survey scans were acquired at an Orbitrap resolution of 
60,000 for an m/z range from 300 to 2000. Tandem MS (MS/MS) data were acquired in 
the linear ion trap using a data dependent method with dynamic exclusion: The top 6 most 
intense ions were selected for collision induced dissociation (CID). CID settings were 35% 
normalized collision energy, 2 Da isolation window, 30 ms activation time and an 
activation Q of 0.250. A window of 45 s was used for dynamic exclusion. Automatic Gain 
Control (AGC) was enabled and target values were 1.00e+6 for the Orbitrap and 1.00e+4 for 
LTQ MSn analysis. Data were recorded with Xcalibur software version 2.1 and analysed 
automatically using the SequestHT search engine with the Decoy algorithm for validation 
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of protein identifications (Proteome Discoverer 1.4; Thermo Scientific, Massachusetts, 
USA). Data were searched against an internal database consisting of CD44 isoforms 
encoded by human proteome obtained from the SwissProt database on 4/12/2017. 
Trypsin was selected as the enzyme, allowing for up to 2 missed cleavage sites, a 
precursor ion mass tolerance of 10 ppm, and 0.6 Da for product ions. 
Carbamidomethylcysteine (+57.02146) was selected as a fixed modification while 
oxidation of methionine (+15.99491), modification of serine and threonine with HexNac 
(+203.07937), HexNacNeuNac (STn) (+494.17479), HexHexNac (T) (+365.13220), 
HexHexNacNeuNac (+656.22761) and HexHexNacNeuNacNeuNac (+947.32303) were 
defined as variable modifications, taking into account our previous publications in bladder 
cancer and O-glycomics analysis (146,151). CD44 is a heavily glycosylated protein and 
the identification of glycosylated peptides is often difficult, therefore, protein grouping 
filters were set to consider peptide identifications with low confidence to avoid loss of 
relevant peptides as false negatives. Identification of specific isoforms was based on the 
presence of isoform specific tryptic peptides and was only considered if the peptide 
spectrum match could be validated manually and presented unambiguous sequence 
coverage. For manual validation, typical carbohydrate fragmentation patterns were also 
considered, including sugar neutral loss, and multiple dehydrations.  
 
3.10. Immunohistochemistry 
 
Formalin-fixed, paraffin-embedded tissue sections (FFPE) were screened for CD44 
expression by immunohistochemistry using the strepavidin/biotin peroxidase method. 
Briefly, 3 μm sections were deparaffinized with xylene, rehydrated with graded ethanol 
series, microwaved for 15 min in boiling citrate buffer (10mM Citric Acid, 0.05% Tween 20, 
pH 6.0, Sigma-Aldrich), and exposed to 3% hydrogen peroxide for 25 min. CD44 was 
detected using a recombinant polyclonal antibody (anti-CD44, 1:4000 in PBS; ab157107; 
Abcam, Cambridge, UK) after incubation overnight at 4°C. Upon digestion with an 
α‐neuraminidase from Clostridium perfringens (Sigma Aldrich, St. Louis, MO, USA) for 4 h 
at 37C, ST and dST antigens were detected using an hybridoma-derived 3C9 antibody 
1:2 overnight at 4C. Also, STn antigen was evaluated using a B72.3 monoclonal antibody 
(Abcam) 0.5ug/mL overnight at 4C. The antigens were identified with UltraVision HRP 
Detection System Kit (Thermo Fisher Scientific, Waltham, MO, USA) followed by 
incubation with 3,3-diaminobenzidine tetrahydrochloride (Impact Dab, Vector 
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Laboratories) for chromogenic development. Finally, the slides were counterstained with 
Harris’s haematoxylin for 1 min. Negative control sections were performed by adding BSA 
(5% in PBS) devoided of primary antibody. The immunostained sections were blindly 
assessed using light microscopy by two independent observers and validated by an 
experienced pathologist. Briefly, a semi-quantitative approach was established to score 
immunoreactivity based on the intensity and extension of the staining. The extension of 
staining was rated in cutoffs of 10%, and staining intensity was rated as follows: negative-
0, weak-1, moderate-2, strong-3. The tumours were then classified based on the 
multiplication of extension evaluation and intensity. Disaccording readings were re-
analysed using a double-headed microscope and consensus was reached. 
 
3.11. In situ proximity ligation assays on tissue sections  
 
The simultaneous detection of CD44 and STn+, ST+/dST+- glycoforms was achieved 
made by in situ proximity ligation assays (PLA), using the Duolink in situ detection 
reagents Red (Olink Bioscience, Uppsala, Sweden) according to the manufacturer’s 
instructions and based on previous reports (143,146,152) FFPE tissues were 
deparaffinized, rehydrated and subjected to acid- and heat-induced antigen retrieval, 
followed by incubation with 3% hydrogen peroxide. Then, tissue sections were incubated 
with blocking solution in aunder humidified atmosphere chamber. CD44, STn and ST/dST 
antigens were detected by indirect PLA using the polyclonal antibody anti-CD44 1:2000 
overnight at 4C (clone ab157107; Abcam, Cambridge, UK), hybridoma-derived 3F1 
antibody 1:4 overnight at 4C, and hybridoma-derived 3C9 antibody 1:2 overnight at 4C, 
respectively. For ST/dST detection, tissues were previously treated with an α-
neuraminidase from Clostridium perfringens (Sigma Aldrich, St. Louis, MO, USA) for 4 h 
at 37C. The PLA probes anti-rabbit MINUS and anti-mouse PLUS were both added and 
sections were incubated at 37C for 1 h. Next, ligation was performed for 30 min at 37 °C, 
and amplification was carried out for 120 min at 37 °C to produce rolling circle products, 
followed by incubation with 4’,6-diamidino-2-phenylindole for 10 min at room temperature 
and sample mountinged for fluorescence microscopy. PLA results were evaluated by two 
distinct observers and validated by an experienced pathologist, who independently 
registered cytolocalizationcolocalization of staining.  
 
 CD44-glycoprofilling: Establishing the molecular basis for targeted therapeutics in bladder cancer| Eliana Soares 
 
36 
 
3.12. Statistical analysis 
 
Statistical analysis was performed using Graphpad prism7 by GraphPad Software, 
Inc. Differences between continuous variables among the evaluated groups were 
accessed by Mann-Whitney non- parametric test for independent samples. Differences 
were considered significant when p<0.05.  
Pair Wise Fixed Reallocation Randomization Test©, calculated by REST software, 
was used to determine the relative gene expression between pre- and post- 
chemotherapy tumours in non- responsive patients. This tool integrates randomization 
and bootstrapping methods that test the statistical significance of calculated expression 
ratios by the hypothesis test p (H1), representing the probability of the alternate 
hypothesis thatwhere  the difference between groups is due only to chance (153). 
  
 
 
 
 
 
Chapter 4 
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4. Results  
Previous work from our group has demonstrated the potential of glycan-affinity 
glycoproteomics nanoplatforms for urinary biomarkers discovery in bladder cancer 
(Appendix 1). Magnetic nanoprobes (MNP) coated with three broad-spectrum lectins 
(Concanavalin A, Wheat Germ Agglutinin, and Sambucus nigra) have been used to 
selectively capture glycoproteins from the urine of low-grade and high-grade non-muscle 
invasive and muscle-invasive BC patients. Glycoproteins were identified by nano-LC 
MALDI-TOF/TOF and data was curated using bioinformatics tools (UniProt, NetOGlyc, 
NetNGlyc, Cytoscape and Oncomine) to highlight clinically relevant species, which 
included the BC stem-cell marker CD44. 
 
4.1. CD44 expression in urine and bladder tumours 
This work starts with the orthogonal validation of previous MS-based results 
(Appendix 1) by determining CD44 levels in the urine of BC patients by slot-blot, as well 
as in the corresponding bladder tumours by immunohistochemistry. According to Figure 5, 
CD44 urinary levels showed a trend increase with the severity of the lesions; however, 
this effect is only significant for high-grade tumours in comparison to controls and low-
grade NMIBC (p<0.05). 
In parallel, immunohistochemical screening of the corresponding bladder cancer 
tissues for CD44 expression demonstrated that CD44 antigen was mainly found at the 
cellular membrane of cancer cells, in accordance with expected cellular location. A 
significant increase in CD44 expression with the severity of the lesions was seen, 
especially in high-grade tumours (p<0,05), thus mimicking urine analysis (Figure 5). More 
importantly, CD44 was not observed in the tumour-adjacent histologically normal 
urothelium of the one case with normal urothelium representation, neither in the most 
superficial lesions, supporting its overexpression in cancer. In superficial tumours, CD44 
was predominantly found in basal layer cells, which frequently harbour more malignant 
clones. Contrastingly, MIBC cells presented an extensive and intense CD44 staining 
without a defined pattern throughout the tumour (Figure 5). These findings agree with 
MNP@ lectins-based glycoproteomics and reinforces the role of CD44 in the context of 
advanced disease (high-grade NMIBC and MIBC). This project further explores the 
expression of CD44 and its splicing variants, including its glycoforms, in BC cell lines 
aiming for CD44-associated signatures associated with more malignant phenotypes. 
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These results were subsequently validated in patient samples envisaging clinical 
translation.  
 
 
Figure 5 Validation of CD44 expression in urine samples and immunohistochemistry of bladder cancer patients. A. 
CD44 urinary levels showed a trend increase with the severity of the lesions; however this effect is only significant for high-
grade tumours in comparison to the control and low-grade NMIBC groups. B. CD44 antigen was mainly found at membrane 
of cancer cells, in accordance with expected cellular location. Again, we observed a significant overexpression of CD44 with 
the severity of the lesions, which is more pronounced for high-grade tumours, thus, mimicking urine analyses. C. In 
superficial tumours, CD44 was predominantly found in cells underlining the basal layer, which have been described to 
harbor more malignant clones. Contrastingly, MIBC cells presented an extensive and intense CD44 expression without a 
defined pattern throughout the tumour. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
 
4.2. CD44 expression in bladder cancer cell lines 
CD44 expression was evaluated in three bladder cancer cell models, two highly 
undifferentiated cells lines isolated from invasive urothelial carcinomas (T24 and HT1376) 
and a more differentiated cell line (5637), isolated from a non-muscle invasive tumour. A 
preliminary screening of these cell lines by western blot highlighted key differences in 
CD44 major bands, demonstrating a different CD44 expression profile between invasive 
(T24 and HT1376) and non-invasive carcinomas derived (5637) cell lines (Figure 6). 
Namely, T24 and HT1376 presented a major band between 75-100 kDa, whereas the 
5637 cell line presented a major band between 100 and 150 kDa. Interestingly, all cell 
lines presented vestigial bands bellow 50 kDa, suggesting the expression of lower 
molecular weight CD44 isoforms (data not shown).  
Complementary analysis by RT PCR, using commercially available probes for all 
forms of CD44 (total CD44), CD44s, CD44v3-v10, and CD44v8-v10 (Figure 4), confirmed 
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the existence of distinct CD44 profiles between invasive and non-invasive cell lines. 
Particularly, invasive T24 and HT1376 exhibit high expression of CD44s, while under-
expressing CD44v3-10 and CD44v8-10. The 5637 cell line presents the exact opposite 
profile (Figure 7). Interestingly, CD44s (39.4 kDa) presents a lower molecular weight when 
compared to CD44v8-10 (53.4 kDa) and CD44v3-10 (76.7 kDa). These observations 
suggest that that more aggressive bladder cancer cells are enriched for lower molecular 
weight CD44 isoforms in comparison to the less aggressive cell line (5637), thus in 
accordance with western blot analysis. Differences between the predicted molecular 
weight and western blot bands may results from marked difference in the number of O-
glycosylation sites (CD44s: 32 putative O-glycosylation sites; CD44v8-10: 79 putative O-
glycosylation sites; CD44v3-10: 140 putative O-glycosylation sites) and possibly O-glycan 
structures.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Western blot of T24 (A), 5637 (B) and HT1376 (C) presenting the most intense band for CD44. T24 present a 
predominant band, with high intensity, between 75-100 kDa. HT1376 exhibits a band pattern similar to T24, with a 
predominant and high intensity band between 75-100 kDa. 5637 shows a predominant band between 150-100 kDa and a 
much less intense band between 75-100 kDa. 
 
Bladder cancer cell lines were submitted to ic50 doses of cisplatin chemotherapy 
and CD44 was evaluated by by western blot in untreated cells (controls) and the remaing 
population after chemotherapy challenge (ic50). According to Figure 8, T24 presented 
higher levels of CD44 in relation to HT1376 and 5637 cell lines. Nevertheless, both the 
CD44 profile and expression levels remained unaltered in all cell lines upon 
chemotherapeutic challenge. Given the higher levels of CD44 in T24 cell line, further 
studies were only conducted using this model. Accordingly, RT PCR analysis of ic50 
resistant T24 subpopulation confirmed the WB results of unchanged CD44 profile, since 
upon chemotherapeutic challenge maintained high expression of CD44s, while under-
expressing CD44v3-v10 and CD44v8-v10. 
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Figure 7 Graphical representation of CD44 isoforms expression in BC cell lines. T24 and HT1376 
express high ratios of CD44s, while under-expressing CD44v3-v10 and CD44v8-v10. 5637 cell line exhibits an 
opposite expression profile. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 CD44 expression in superficial tumour derived cell line 5637 and muscle-invasive bladder cancer derived 
T24 and HT1376 cell lines. CD44 levels are significantly higher in T24 cell line in comparison to 5637 and HT1376 cell 
lines. Nevertheless, CD44 levels did not vary for any cell line after exposure to IC50 doses of Cisplatin. 
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4.3. O-glycome and glycoproteomics profile of CD44 
A glycoproteomics approach was used to validate CD44 isoforms previously 
accessed by real-time PCR in T24 cells (CD44 v3-v10, CD44 v8-v10 and CD44s) and to 
broaden the current knowledge on this field. T24 cell line was elected for this preliminary 
glycoproteomics analysis based on its higher CD44 expression in comparison to other cell 
lines (Figure 8). Nevertheless, the high glycosylation degree of this protein (approximately 
150 glycosylation sites for the canonical isoform) poses a significant hurdle for isoforms 
identification by mass spectrometry (154). Therefore, an O-glycomics approach was first 
performed to highlight the most abundant glycoforms produced by T24 cells.  Accordingly, 
the most predominant forms included the mono- and di-sialylated T antigens (m/z=954 
and m/z=1315, respectively) that have been previously found overexpressed in advanced 
bladder tumours (146,155) In addition, this experiment also demonstrate the presence of 
STn antigen (m/z=783), including its monoacetylated form (m/z=825), which are important 
for disease progression and dissemination (126,129,156,157) Dissialylated core 2 
(m/z=1764) and fucosylated core 1 (m/z=767) glycans were also detected, but their 
biological and clinical significance remains unknown in bladder cancer. In addition there 
was a minor expression of more elongated, sialylated and fucosylated O-glycoforms 
(Figure 9), whose role in bladder cancer also warrants future clarification.  
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Figure 9 Mass spectrometry spectra of identified O-glycoforms in T24 cells. The most predominant forms included the 
mono- and di-sialylated T antigens (m/z=954 and m/z=1315, respectively), dissialylated core 2 (m/z=1764) and fucosylated 
core 1 (m/z=767). In addition, there is minor expression of more elongated, sialylated and fucosylated O-glycoforms. 
 
In parallel, CD44 and its isoforms were immunoprecipitated from membrane 
proteins that were isolated from protein lysates by differential ultracentrifugation. CD44 
immunoprecipitates were first analyzed by western blot (Figure 10A), which confirmed the 
main band between 75 and 100 kDa but also several bands at both higher and, 
particularly, lower molecular weights, suggesting a broader array of CD44 iso- and 
glycoforms. Then CD44 isoforms were separated by SDS-PAGE, bands were excised 
from gel, digested with trypsin and identified by nano-LC MS/MS.  Take into account that 
the CD44 isoforms definition is governed by variable exons encoding for a significant 
number of O-glycosylation sites, information on the glycome was comprehensively 
included for protein identification. This approach led to the unequivocal identification of 12 
isoforms. In addition to confirming the expression of CD44v3-v10, CD44v8-10 and CD44s, 
previously accessed by RT-PCR targeted approach, it included CD44v10, CD44 NCBI 
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Transcript 7 and CD44RC and also Uniprot isoforms 2, 3, 5, 7, 8, 9, 13 and 14 (predicted 
isoforms) (Figure 10A), information summarized in table 2. Interestingly, the most 
predominant band between 75 and 100 kDa in western blots, comprehended isoforms 3, 4 
(CD44v8-10 also analyzed by RT-PCR), isoform 7, and isoform 12/15 (CD44s also 
analyzed by RT-PCR). More importantly, many CD44 isoforms spanned different 
molecular weights most likely reflecting distinct O-glycosylation patterns. In addition, 
glycopeptides carrying previously described cancer-associated glycans could be identified 
for all isoforms. Specifically, the short isoform CD44s, associated with muscle invasive 
phenotypes and chemoresistance, has demonstrated specific O-glycosylation sites 
exhibiting di-sialyl-T and STn glycoforms (Figure 10B and C). 
 
 
Figure 10 Identification of CD44 isoforms by mass spectrometry. A. A targeted proteomics approach led to the 
unequivocal identification of 12 CD44 isoforms; namely, CD44v3-v10, CD44v8v-v10, CD44s, CD44v10, CD44 NCBI 
Transcript 7, CD44RC, and Uniprot isoforms 2, 3, 5, 7, 8, 9, 13 and 14 (predicted isoforms). B. MS/MS spectrum of CD44s 
specific glycopeptide glycosylated with the STn antigen as well as Tn and T. C. MS/MS spectrum of CD44s specific 
glycopeptide glycosylated with the ST antigen. 
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Table 3 - Representation of CD44 isoforms analysed compared to decribed and predicted isoforms 
Predicted 
CD44 isoforms 
CD44 described 
isoforms 
Identified by MS/MS Identified by PCR 
Isoform 1 Isoform 1     
Isoform 2  Isoform 2  
Isoform 3  Isoform 3  
Isoform 4 Isoform 4 
(CD44v3-v10) 
Isoform 4  Isoform 4 
Isoform 5  Isoform 5  
Isoform 6    
Isoform 7  Isoform 7   
Isoform 8  Isoform 8   
Isoform 9   Isoform 9   
Isoform 10 Isoform 10 
(CD44v8-v10)  
Isoform 10 Isoform 10  
Isoform 11 Isoform 11 
(CD44v10)  
Isoform 11   
Isoform 12  Isoform 12 
(CD44s) 
Isoform 12  Isoform 12/15  
Isoform 13    Isoform 13   
Isoform 14   Isoform 14   
Isoform 15  Isoform 15 
(CD44st) 
Isoform 15  Isoform 12/15 
Isoform 16      
Isoform 17     
Isoform 18 Isoform 18 
CD44 NCBI Transcript 7 
Isoform 18  
 
Isoform 19 Isoform 19 
(CD44RC)  
Isoform 19    
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To validate the existence of abnormally glycosylated CD44, muscle-invasive 
bladder tumour tissues were then screened for CD44 and mono- and di-sialyl-T 
glycoforms, which are the most abundant glycans in O-glycomics analysis. In addition, the 
sialyl-Tn antigen, which has been previously associated with more aggressive 
phenotypes, was also evaluated. Two complementary validation strategies were applied, 
first consecutive tumour tissues were screened for CD44 and cancer associated O-
glycans by immunohistochemistry. In parallel, the same tumour sections were screened 
for CD44 and the targeted glycans by in situ proximity ligand assays (PLA), which allowed 
the simultaneous detection of both targets when in close proximity. Since there are no 
monoclonal antibodies for mono- and di-sialyl-T antigens, the tissues were first digested 
with an alpha-neuraminidase to expose the T antigen. Subsequently, detection was 
conducted using a commercial available against the T antigen. Importantly, prior to 
analyses, the tumour tissues were found to be negative or present just vestigial T antigen 
expression, in accordance to previous observations from our group (146). Upon 
neuraminidase digestion, T antigen presented an extensive and intense expression 
consistent with the presence of ST and/or dST antigens. Immunohistochemistry analyses 
further demonstrated the coexpression of the glycans and CD44 in the same tumour 
areas, which was confirmed by PLA analyses (Figure 11). These findings support the 
existence of CD44 carrying cancer-associated glycoforms in bladder tumours and validate 
the results of the proteomics approach.  
In summary, glycomics and glycoproteomics analysis confirmed the existence of 
CD44 variants previously observed by RT-PCR, which have allowed distinction between 
more aggressive and superficial cancer cells, In particular, it confirmed the presence of 
CD44s, which has been associated with cell lines derived from muscle invasive tumours 
and chemoresistance. Nevertheless, it also highlighted the presence of several other 
isoforms, which warrant comprehensive evaluation in future studies. Moreover, it 
demonstrated that CD44s was glycosylated with sialylated short-chain O-glycans 
frequently present in invasive tumours, providing key insights for designing highly specific 
targeted therapeutics.  
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Figure 11 In situ proximity ligand assay and immunohistochemistry for the simultaneous detection of CD44/ST and 
dST as well as CD44/STn glycoforms. Two complementary validation strategies were applied: first consecutive tumour 
tissues were screened for CD44 and cancer associated O-glycans by immunohistochemistry (right); second, the same 
tumour sections were screened for CD44 and the targeted glycans by in situ proximity ligand assays (left), which allowed 
the simultaneous detection of both targets when in close proximity. Results showed the co-expression of CD44, ST, and 
dST (A) as well as STn and CD44 (B) in the same tumour areas and support the existence of CD44 carrying cancer-
associated glycosylation in bladder tumours. 
 
 
4.4. CD44 expression in bladder cancer tumours 
To explore the CD44 expression profile in bladder tumours, western blot analysis 
was performed using extracted proteins from tumours representative of high grade 
tumours (more aggressive) from all stages of the disease . In agreement with T24 and 
HT1376 cell lines, bladder tumours also presented a main band between 75 and 100 kDa, 
denoting a common ground at the CD44 level (Figure 6 and 12). A major band at 250 kDa 
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was also observed in bladder tissues that may correspond to CD44 canonical form, which 
presents approximately 150 putative O-glycosylation sites. Interestingly, bladder tumours 
also exhibit low molecular weight forms (bellow 37 kDa) of CD44, as also previously 
observed for T24 cell line (Figure 10 and 12). These may correspond to truncated and/or 
poorly glycosylated CD44 isoforms, whose nature warrant comprehensive elucidation in 
future studies. Nevertheless, these protein were isolated from FFPE tissues, which may 
ultimately lead to proteolysis and the accumulation of low molecular weight species. 
Therefore, studies using freshly collected surgical specimens will be required to validate 
these findings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Western blot analysis of bladder cancer tumours. CD44 expression patterns are unaltered by disease stage. 
However, all major CD44 bands in bladder tumour samples are of low molecular weights. 
 
Nevertheless, particular emphasis was given to confirming by RT-PCR the 
associations between CD44v3-10, CD44v8-10 and CD44s with the severity of the lesions, 
suggested upon the analysis of cell models. Accordingly, NMIBC presented high levels of 
CD44v3-v10, while under-expressing CD44v8-v10 and CD44s. In turn, MIBC presents 
significantly higher levels of CD44s (p<0.05) compared with NMIBC (Figure 13). 
Moreover, no differences were found regarding CD44v3-v10 and CD44v8-v10 between 
NMIBC and MIBC. These observations support the existence of a CD44v8-10Low, 
CD44v3-10Low and CD44shigh phenotype for muscle invasive tumours, which contrasts with 
the CD44v8-10high, CD44v3-10high and CD44slow phenotype presented by NMIBC. 
A group of 10 patients non-responsive to neo-adjuvant chemotherapy with 
cisplating were selected for CD44 isoform characterization, and analysis was performed in 
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tumours before and after chemotherapy. Upon chemotherapeutic challenge, total CD44 
and CD44s expression showed approximately a 3-fold-increase, while CD44v3-v10 and 
CD44v8-v10 demonstrated a 50% decrease (Figure 14). These results suggests that 
CD44s might have a role in chemoresistance to cisplatin in bladder cancer patients, 
supporting previous observations using T24 cell model. 
 
Figure 13 Graphic schematization of CD44 isoforms expression in NMIBC and MIBC. NMIBC exhibited high 
expressions of CD44v3-v10 and low CD44s, while MIBC low expressions of CD44v3-v10 and high expression of CD44s. 
MIBC expressed higher levels of CD44s compared to NMIBC *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Graphic schematization of CD44 expression in pre- and post-chemotherapy tumour samples. Both total 
CD44 and CD44s show a 3-fold increased expression upon chemotherapeutic challenge, while CD44v3-v10 and CD44v8-
v10 had a 50% decrease. 
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In summary, patient samples analysis demonstrates a CD44 remodelling 
accompanying muscle invasion, translated by the transition from high-molecular weight to 
low molecular weight isoforms, as previously suggested using cell models. More 
importantly, data suggests that CD44s low molecular weight isoforms may be a marker of 
chemoresistant clones. 
  
 
  
 
 
 
Chapter 5 
DISCUSSION, CONCLUDING REMARKS AND 
FUTURE PERSPECTIVES 
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5. Discussion, concluding remarks and future 
perspectives 
 
 Bladder Cancer (BC) presents one of the highest recurrence rates amongst solid 
tumours, and constitutes the second deadliest disease of the genitourinary track. The 
introduction of molecular models for disease management and effective targeted 
therapeutics remains a challenging aspect due to significant inter and intra-tumour 
molecular heterogeneity. Therefore, the management of BC patients presents significant 
hurdles due to high recurrence rates, rapid progression, dissemination, and poor response 
to chemotherapy. As previously described, several studies have demonstrated that CD44 
has an important role in carcinogenesis, being a biomarker of undifferentiated stem-like 
cell phenotypes (26,158). As such, CD44 offers the opportunity for specifically target more 
malignant tumour cell phenotypes, including chemoresistant clones (159). Importantly, 
CD44 gene suffers extensive alternative splicing, generating several isoforms whose 
biological and clinical role in BC is still poorly understood. These observations allied to 
conflicting reports has hampered the true development of targeted therapies involving this 
marker. These discrepancies can be explained by the lack of standard 
immunohistochemical assays, the use of antibodies with different specificities, and 
differences in the clinicopathological status of bladder tumours used in the different 
studies. For instance, CD44s expression was associated with higher disease grade, 
stage, and density of tumour infiltrating lymphocytes, as well as with shorter overall 
survival, while CD44v6 expression was associated with better prognosis, lower grade and 
increased overall survival (81). Contrastingly, other authors reported that the loss of 
CD44v6 expression is an independent adverse predictor of recurrence and overall 
survival, further suggesting that routine evaluation of CD44v6 could be important for 
identifying high-risk patients which would benefit from more aggressive therapeutic 
approaches. Also, it was hypothesised that CD44v6 expression could be a much better 
predictor of recurrence than BC grade (82). 
In order to gain knowledge regarding CD44 and its isoforms relevance in BC, a 
preliminary study concerning CD44 expression in urine and bladder tumours 
demonstrated that CD44 urinary levels increased with the severity of the lesions; however, 
this effect is only significant for high-grade tumours in comparison to controls and low-
grade NMIBC. Furthermore, tumour expression of CD44 also increases with the severity 
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of the lesions, which is more pronounced for high-grade tumours, thus, mimicking urine 
analysis. More importantly, CD44 was not observed in the tumour-adjacent histologically 
normal urothelium of the one case with normal urothelium representation, neither in the 
most superficial lesions, supporting its overexpression in cancer. In superficial tumours, 
CD44 was predominantly found in basal layer cells, which has been described to harbour 
more malignant clones (80,81). Contrastingly, MIBC cells presented an extensive and 
intense CD44 staining without a defined pattern throughout the tumour. Given these 
insights, this work brings together a targeted-analysis of CD44 isoforms present in bladder 
cancer cell lines and bladder tumours, as well as a non-target, more explorative approach 
to broaden our knowledge on the isoforms present in both cell lines and patient samples. 
Accordingly, a short CD44 isoform, specifically CD44s, is predominantly expressed by 
more aggressive cell lines and tumours. On the other hand, more elongated isoforms 
(CD44v3-10 and CD44v8-10) have been found associated with more superficial lesions, in 
both cell models and in human tumours. These observations strongly suggest that the 
acquisition of invasive and/or other more aggressive traits may be accompanied by a 
remodelling of CD44 expression patterns towards shorter isoforms. Moreover, upon 
chemotherapeutic challenge, CD44s becomes overexpressed or unchanged in BC cell 
lines and in muscle-invasive bladder tumours that do not respond to chemotherapy, 
highlighting its relevance in the acquisition of chemoresistance traits in bladder cancer. Of 
note, CD44s has been previously associated with undifferentiated bladder cancer cells, 
higher disease stage and grade, depth of invasion, density of tumour infiltrating 
lymphocytes and short overall survival (80,81,160). However, other reports suggest that 
increased CD44s is related to low grade tumours and increased overall survival (83,161). 
Conflicting results are also found in other tumours models as hepatocellular, breast and 
colorectal cancers. Particularly, some studies indicate that CD44s overexpression is 
related to invasion, lymph node metastasis, aggressive disease, and expression of 
mesenchymal markers (162,163), while other studies suggest that CD44s is related to low 
grade tumours and higher overall survival (164). Interestingly, we observed that T24 cells 
that overexpress CD44s after chemotherapy challenge concomitantly activate a series of 
epithelial-to-mesenchymal (EMT)-related genes (165), thereby acquiring more motile 
phenotypes. These observations support that CD44s overexpression may be associated 
with invasive traits, at least for certain bladder cancer cells subpopulation. In agreement 
with these observations, the functional role for CD44 alternative splicing during EMT has 
already been demonstrated in breast cancer (166). Particularly, upon EMT programs 
activation a switch in CD44 isoform expression from CD44 variants to CD44s occurs. 
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Importantly, the overall level of CD44 protein did not significantly change during this 
process. Furthermore, CD44s expression, but not CD44 variants expression, was 
functionally linked to Akt activation, upregulation of anti-apoptotic molecules and 
apoptosis resistance. Given these insights, it is possible that a chemotherapy-induced 
EMT activation could lead to CD44s overexpression in bladder cancer. As such, CD44s 
seems to hold tremendous potential to target more aggressive and chemoresistant BC 
cells. Future studies should now focus on disclosing a link between CD44s 
overexpression and both invasion and chemoresistance. Moreover, a glycoproteomics 
approach has disclosed a wider array of isoforms for T24 cells line, including lower 
molecular weight protein species that should also be addressed in other cell lines and 
bladder tumours to provide a more comprehensively addressed envisaging clinically 
relevant and biomarkers.   
In addition to isoform remodelling CD44 may also experience glycome remodelling 
accompanying significant alterations at this level experienced by bladder cancer cells 
(18,145,146). As such, the combined knowledge of clinically relevant isoforms of CD44 in 
BC with its associated glycosylation can generate highly specific targets for aggressive 
BC clones. Supporting this hypothesis, previous work from our group has also highlighted 
that CD44 presents the cancer-associated STn antigen as posttranslational modifications 
(145,146). The O-glycome characterization of aggressive BC cell line T24 has now shown 
the overexpression of sialylated short-chain of O-glycans, as ST, dST and STn, mimicking 
its expression in advanced stage bladder tumours (126,146). Downstream 
glycoproteomics studies confirmed the existence of CD44 isoforms carrying these 
glycans, including CD44s. The presence of CD44-STn and CD44-ST and/or dST was also 
confirmed in muscle invasive bladder tumours. As such, future studies should devout to 
explore the functional role of CD44s in BC progression, as well as glycomapping its 
structure, envisaging highly specific targets. Silencing of long CD44 isoforms in superficial 
cell lines overexpressing these glycans is currently being evaluated as a starting point for 
functional studies. Based on this molecular rational, specific antibodies against CD44s 
glycoforms could be developed. Such ligands may either be used to block oncogenic 
signalling transduction pathways potentially mediated by CD44, deliver drugs to more 
aggressive and chemoresistant clones and/or elicit immune responses against these cells. 
Furthermore, the generated knowledge could be employed for addressing metastatic 
disease, since CD44 could be functionally associated with metastatic propagation by 
stem-like cancer cells in bladder cancer.  
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Abstract 
Bladder Cancer (BC) presents one of the highest recurrence rates amongst solid tumours 
and constitutes the second deadliest disease of the genitourinary track. Non-invasive 
identification of patients facing disease recurrence and/or progression remains one of the 
most critical and challenging aspects in disease management. To contribute to this goal, we 
demonstrate the potential of glycan-affinity glycoproteomics nanoplatforms for urinary 
biomarkers discovery in bladder cancer. Briefly, magnetic nanoprobes (MNP) coated with 
three broad-spectrum lectins, namely Concanavalin A (ConA; MNP@ConA), Wheat Germ 
Agglutinin (WGA; MNP@WGA), and Sambucus nigra (SNA; MNP@SNA), were used to 
selectively capture glycoproteins from the urine of low-grade and high-grade non-muscle 
invasive as well as muscle-invasive BC patients. Proteins were identified by nano-LC 
MALDI-TOF/TOF and data was curated using bioinformatics tools (UniProt, NetOGlyc, 
NetNGlyc, Cytoscape and Oncomine) to highlight clinically relevant species. Accordingly, 
63 glycoproteins were exclusively identified in cancer samples compared with healthy 
controls matching in age and gender. Specific glycoprotein sets exclusively found in low-
grade non-muscle invasive bladder tumours may aid early diagnosis, while those only 
found in high-grade non-invasive and muscle-invasive tumours hold potential for accessing 
progression. Amongst these proteins is bladder cancer stem-cell marker CD44, which has 
been associated with poor prognosis in bladder tumours. Orthogonal validation studies by 
slot-blotting demonstrated an elevation in urine CD44 levels of high-grade patients, which 
became more pronounced upon muscle-invasion, in mimicry of the primary tumour. These 
observations demonstrate the potential of MNP@lectins for identification of clinically 
relevant glycoproteomics signatures in bladder cancer. Future clinical validation in a larger 
and well characterized patient subset is required envisaging clinical translation of the 
results.  
 
 
 
 
 
 CD44-glycoprofilling: Establishing the molecular basis for targeted therapeutics in bladder cancer| Eliana Soares 
 
78 
 
 
Introduction 
Bladder cancer (BC) is the second most deadly malignancy of the urinary tract [1]. Patients 
diagnosed with low-grade non-muscle invasive BC (NMIBC) generally face better 
prognosis, whereas those with high-grade lesions are frequently burdened by significant 
recurrences, generally accompanied by progression to muscle invasion (MIBC) and 
metastasis [2]. As such, these patients are subjected to several post-operative cycles of 
intravesical therapy proceeded by intensive and invasive follow-up interventions [2]. The 
development of non-invasive tools supporting the differentiation between low and high-
grade lesions, as well as the early identification of patients at risk of progression, remains a 
critical aspect for disease management [3].  
Urine is easily accessible and, in bladder cancer cases, is in direct contact with the tumour, 
thereby providing a key source of biomarkers for addressing the above mentioned 
difficulties [4]. Moreover, the human urine proteome is well characterized, supporting 
proteomics-based biomarker studies [5]. Interestingly, the most relevant targets arising 
from these studies include several glycoproteins, such as members of the apolipoprotein 
family, fibrinogen chains, alpha-1-antitrypsin, alpha-2-macroglobulin, and uromodulin [5, 
6]. Nevertheless, these biomarkers may be reflective of haematuria and have also been 
associated with kidney disease (e.g. apolipoproteins, uromodulin, or alpha-1-antitrypsin) 
and other pathologies [6]. As such, current urine biomarkers lack the necessary sensitivity 
and specificity for clinical use; however, their incorporation in multi-biomarker panels may 
provide the necessary molecular context for more effective applications. However, the lack 
of efficient enrichment strategies remains one of the most critical aspects underlying the 
identification of cancer-specific biomarkers, generally present in minute amounts (nano-
femtomolar range) in bodily fluids such as urine [7].  
Targeting glycan moieties in cancer-associated glycoproteins holds tremendous potential to 
overcome these limitations, while providing an important source of clinically relevant 
biomarkers [8]. Moreover, the identification of disease-associated glycoforms may further 
improve the biomarker potential of already proposed urine glycobiomarkers. Accordingly, 
several decades of research, mostly using lectins and antibodies for tissue screening, have 
disclosed a plethora of alterations in membrane proteins glycosylation associated with 
bladder cancer [3]. Namely, we have reported that disease progression to invasion and 
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dissemination is accompanied by the overexpression of short-chain sialylated O-glycans, 
associated with poor prognosis [9-11]. Lectin-enrichment targeting these glycans further 
enabled the identification of clinically relevant glycoproteins in patient samples, including 
several integrins, cadherins, the stem cell marker CD44 and MUC16 [12, 13]. Taken 
together, our studies demonstrated the importance of pre-enrichment strategies for 
downstream comprehensive glycoproteomics approaches envisaging biomarker discovery 
[12-14]. Concomitantly to O-glycan alterations, advanced stage bladder cancer cells also 
experience N-glycome remodelling, including changes in mannose core, branching, 
elongation and degree of fucosylation and sialylation [3]. However, the nature of the 
glycoproteins exhibiting these alterations is still poorly understood. Nevertheless, we 
hypothesize that abnormally glycosylated proteins may be secreted or shed from the 
primary tumour into bodily fluids, constituting an important source of potentially relevant 
urine glycobiomarkers.  
Building on these insights, our group has developed lectin functionalized magnetic 
nanoprobes for glycoproteomics research, which have demonstrated enhanced sensitivity 
in comparison to conventional enrichment strategies [15, 16]. Herein, we aim to explore 
the potential of these nanoplatforms to highlight the existence of glycoprotein signatures 
associated with bladder cancer stage and grade. We envisage that this preliminary 
approach may provide the necessary analytical rationale for more in depth translational 
studies. 
 
Material and Methods 
Patient Samples 
Between 2010 and 2011, thirty-one first void urine samples without visible signs of 
haematuria were prospectively collected before surgery of bladder cancer male patients 
with mean age of 70 (range, 45–89) years, attending the Portuguese Institute of Oncology 
of Porto (IPO-Porto; Portugal). Only patients that had not been previously submitted to 
neoadjuvant therapy were included. Corresponding formalin-fixed paraffin embedded 
(FFPE) tumours were also obtained for this study. Based on the World Health Organization 
urothelial carcinoma grading and staging criteria, three different groups were considered in 
this study, namely low-grade (n=15) and high grade (n=9) non-muscle-invasive bladder 
tumours (NMIBC) and muscle-invasive (n=7) tumours (MIBC). An additional 15 urines 
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were obtained from healthy control male volunteers, mean age of 68 (range 41-82) years. 
All procedures were performed under the approval of the institution ethics committee and 
upon patients’ informed consent. All clinicopathological information was obtained from 
patients’ clinical records. 
 
Isolation of Urine Proteins 
Five to forty millilitres of collected urine were centrifuged at 5000g for 40 min at 4 °C to 
remove cells and debris, desalted on Amicon Ultra 10 kDa centrifugal filters (Merck 
KGaA, Darmstadt, Germany) and proteins were resuspended on 50 mM Ammonium 
bicarbonate (pH 7.8, Sigma-Aldrich, St. Louis, MO, EUA). Protein quantification was 
accessed using the DC Protein assay (Bio-Rad, Hercules, CA, USA) and proteins content 
was normalized in relation to creatinine.  
 
Total Sialic acids  
Total sialic acids (TSA) were determined by fluorimetry as previously described [15, 16]. 
All solutions were precooled in an ice bath. Twenty microliters of sodium periodate 
solution (10 mM, Sigma-Aldrich) were added to 30 l of glycoconjugate sample (10–200 
g) placed in a 2 mL polypropylene test tube. The solution was chilled in the ice bath for 
45 min. The reaction was stopped by adding 100 l of 50 mM sodium thiosulfate (Sigma-
Aldrich), 500 l of 4.0 M ammonium acetate (pH 7.5, Sigma-Aldrich) and 400 l of an 
ethanolic solution of 100 mM acetoacetanilide (Sigma-Aldrich), followed by incubation 
for 10 min at room temperature. The fluorescence intensities of the solution were measured 
at 471 nm with an excitation wavelength of 388 nm. Detection limits of the determination 
were obtained according to the relative fluorescence of sample solution to a sample blank 
prepared under identical conditions. TSA content was normalized in relation to the 
creatinine content in the samples. 
 
Synthesis of lectin functionalized magnetic nanoparticles (MNP@ConA; 
MNP@WGA; MNP@SNA) 
Lectin functionalized ferromagnetic nanoparticles were synthetized as previously described 
by Ferreira et al. (2011) [15] and Cova M et al. (2015) [16]. Briefly, the iron oxide 
magnetic core of the MNPs was synthesized by coprecipitation of FeCl2 and FeCl3 (Sigma-
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Aldrich) under alkaline conditions and coated with amorphous silica to prevent particle 
clustering and ensure their chemical stability. Derivatization was achieved by reaction with 
tetraethyl orthosilicate (TEOS, Sigma-Aldrich) under alkaline conditions with 
trimethylamine (Sigma-Aldrich) as catalyst. Subsequently, the silica-coated nanoparticle 
surface was functionalized with amine groups with 3-aminopropyltrimethoxysilane (APS, 
Sigma-Aldrich) to reduce nonspecific interactions with the target proteins. Successful 
synthesis and surface modification of the MNP matrix was ensured by step-by-step 
monitorization with Fourier transform infrared (FT-IR) spectroscopy. The size and shape 
of the MNPs was determined by transmission electron microscopy. The MNPs exhibited 
relatively narrow size distribution and an average diameter of 14±3 nm, thus confirming 
their nanoscale dimensions. The MNPs were then dispersed in dimethyl sulfoxide (DMSO, 
Sigma-Aldrich) and their surface was activated with suberic acid bis-N-
hydroxysuccinimide ester (DSS, Sigma-Aldrich), washed thoroughly with DMSO, and 
incubated with Concanavalin A (ConA; Vector Laboratories, Burlingame, CA, USA), 
Wheat Germ Agglutinin (WGA; Vector Laboratories), and Sambucus nigra (SNA; Vector 
Laboratories) (1 mg/mL in binding buffer; Table 1S) at 4 °C for 12 h to produce 
MNP@ConA, MNP@WGA, and MNP@SNA particles, respectively. Binding of the 
lectins at the cells surface was confirmed by FT-IR and UV spectroscopy at 280 nm. The 
amount of bounded lectin was indirectly estimated from the conjugation supernatant.  
 
Urine Glycoprotein enrichment with MNP@lectins 
Proteins isolated from the urine of male individuals (n=5) were polled together according 
to the following groups: i) Controls; ii) low-grade NMIBC; iii) high-grade NMIBC; iv) 
MIBC. Protein extracts (100 g) were diluted in 500 μL of lectin binding buffers and 
incubated with 1 mg of MNP@lectins at 4°C for 30 min. Specifically, ConA binding 
buffer was 20 mM Tris, 500 mM NaCl, 5 mM MgCl2, 5 mM MnCl2, and 5 mM CaCl2, pH 
7.45. WGA binding buffer was 20 mM Tris, 150 mM NaCl, and 0.05% Tween-20, pH 
7.45. SNA binding buffer was 20 mM Tris, 150 mM NaCl, and 0.05% Tween-20, pH 7.45. 
The MNP were then pulled to the tube walls under the influence of a strong magnetic field, 
allowing an easy and complete removal of the supernatant. The unbound proteins were 
removed by washing three times with 200 μL of wash buffer (0.05% Tween-20 in binding 
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buffer). The glycoproteins were recovered with specific elution buffers for each ligand as 
previously reported [15, 16]. 
 
Protein identification and data curation 
The proteins recovered from MNP@lectins were first reduced upon incubation with 5 mM 
dithiothreitol (DTT, Sigma-Aldrich) at 75ºC for 1 h, then alkylated with 20 mM 
iodoacetamide (Sigma-Aldrich) at room temperature in the dark for 2 h and digested with 
trypsin (Promega, Madison, WI, USA) for 37.0°C overnight. Protein identification was 
performed as previously described by our group [16]. Tryptic digests were separated with a 
C18 Pepmap (Dionex) column on an Ultimate 3000 (Dionex/LC Packings, Sunnyvale, CA) 
nano-HPLC, and fractions were collected with a Probot (Dionex/LC Packings, Sunnyvale, 
CA) directly onto a matrix-assisted laser desorption ionization (MALDI) plate. The 
MALDI-TOF/TOF (time-of-flight) mass spectrometry (MS) analysis was performed on a 
4800 MALDI-TOF/TOF Analyzer (Applied Biosystems, Foster City, CA). The MS and 
MS/MS spectra acquired were processed and analyzed by the Global Protein Server 
Workstation (Applied Biosystems). LC-MALDI-MS/MS runs were done in triplicates for 
each MNP@lectin (ConA, WGA, SNA) and experimental condition (control, low-grade 
NMIBC, high-grade NMIBC; MIBC). Protein identification was achieved with a search 
performed against the Swiss-Prot protein database (March 2009, 428 650 entries) for 
Homo sapiens. The final list includes proteins common to all three independent LC-
MALDI-MS/MS runs, which were then queried using the “Retrieve ID/mapping” tool of 
UniProtKB [17] for membrane glycoproteins with extracellular domain prone to exhibit or 
secreted glycoproteins [14]. The identified glycoproteins were then screened for putative 
N-glycosylation sites using NetNglyc 1.0 server 
(http://www.cbs.dtu.dk/services/NetNGlyc), an artificial neural network that examines the 
sequence context of Asn-X-Ser/Thr (where X is not Pro) sequons [18]. O-glycosylation 
was predicted using the NetOglyc 4.0 server (http:// www.cbs.dtu.dk/services/NetOGlyc) 
that produces neural network predictions of mucin-type GalNAc O-glycosylation sites in 
mammalian proteins [19]. Online bioinformatics tools Oncomine [20] and the ClueGO and 
CluePedia apps for Cytoscape (http://www.cytoscape.org/) [21, 22] allowed narrowing the 
identified species to glycobiomarkers with non-invasive clinical potential, as previously 
described by us [14]. 
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Slot-Blot analysis 
Urine proteins were slot-blotted on a nitrocellulose membrane (Whatman, Protan; pore size 
0.45 m) using the Hybri-slot apparatus (21052-014; Gibco BRL, Life Technologies, 
Waltham, MA, USA). Fetuin from fetal calf serum and deglycosylated bovine serum 
albumin (both purchased at Sigma-Aldrich) were used as positive and negative controls, 
respectively. Nonspecific binding was blocked with Carbo-Free Blocking Solution (SP-
5040, Vector Laboratories) for 30 minutes at room temperature. The samples were 
incubated with biotinylated ConA, WGA and SNA lectins (Vector Laboratories) for 30 
minutes at room temperature. Membranes were then washed with TBS-T (TBS with 0.5 % 
Tween 20) and incubated with VECTASTAIN® ABC (Peroxidase, PK-6100, Vector 
Laboratories) for 30 minutes at room temperature. Lectin-affinity was determined using 
biotin/avidin interaction. Samples were also screened for CD44 using a recombinant 
monoclonal antibody (anti-CD44, 1:150 in PBS; EPR1013Y; Abcam, Cambridge, UK) and 
a goat anti-rabbit IgG (H+L) Secondary Antibody, HRP (Invitrogen, Carlsbad, CA, USA). 
Reactive bands were detected by enhanced chemiluminescence ECL (Amersham 
Pharmacia Biotech Inc, Piscataway, NJ, USA) according to the manufacturer's instructions. 
Images were recorded using X-ray films (Kodak Biomax light Film, Sigma-Aldrich). The 
films were scanned in Molecular Imager Gel Doc XR+ System (Bio-Rad) and analyzed 
with QuantityOne software (v 4.6.3, Bio-Rad). The results reflected the average of at least 
three independent replicates. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue sections (FFPE) were screened for CD44 
expression by immunohistochemistry using the strepavidin/biotin peroxidase method. 
Briefly, 3 μm sections were deparaffinized with xylene, rehydrated with graded ethanol 
series, microwaved for 15 min in boiling citrate buffer (10mM Citric Acid, 0.05% Tween 
20, pH 6.0, Sigma-Aldrich), and exposed to 3% hydrogen peroxide for 25 min. CD44 was 
detected using a recombinant monoclonal antibody (anti-CD44, 1:4000 in PBS; ab157107; 
Abcam, Cambridge, UK) after incubation overnight at 4°C. Upon digestion with an 
α‐neuraminidase from Clostridium perfringens (Sigma Aldrich, St. Louis, MO, USA) for 4 
h at 37ºC, ST and dST antigens were detected using an hybridoma-derived 3C9 antibody 
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1:2 overnight at 4ºC. The antigens were identified with UltraVision HRP Detection System 
Kit (Thermo Fisher Scientific, Waltham, MO, USA) followed by incubation with 3,3-
diaminobenzidine tetrahydrochloride (Impact Dab, Vector Laboratories) for chromogenic 
development. Finally, the slides were counterstained with Harris’s haematoxylin for 1 min. 
Negative control sections were performed by adding BSA (5% in PBS) devoided of 
primary antibody. The immunostained sections were blindly assessed using light 
microscopy by two independent observers and validated by an experienced pathologist. 
Briefly, a semi-quantitative approach was established to score immunoreactivity based on 
the intensity and extension of the staining. The extension of staining was rated in cutoffs of 
10%, and staining intensity was rated as follows: negative-0, weak-1, moderate-2, strong-3. 
The tumours were then classified based on the multiplication of extension evaluation and 
intensity. Disaccording readings were re-analyzed using a double-headed microscope and 
consensus was reached.  
 
Statistical analysis and data mining 
Statistical analysis was performed using Graphpad prism7 by GraphPad Software, Inc. 
Differences between continuous variables among the evaluated groups were accessed by 
Mann-Whitney non- parametric test for independent samples. Differences were considered 
significant when p<0.05. 
 
Results 
To highlight the potential of glycan-affinity glycoproteomics nanoplatforms for biomarker 
discovery in BC, we have prospectively collected urine samples from low-grade and high-
grade NMIBC and MIBC patients. A significant increase in protein content was observed 
in these urines in comparison to healthy controls matching in age and gender (Figure S1A-
Supporting Information). Moreover, proteinuria increased with the severity of the lesions, 
in accordance with previous reports [23]. Concomitantly, the urines of cancer patients 
presented higher sialic acids content in comparison to the controls, which also was more 
pronounced in high-grade NMIBC and MIBC (Figure S1B – Supporting Information), 
suggesting profound alterations in the urine glycome. Urine glycoproteins were then 
isolated after dialysis and pooled together in accordance with the histopathological natures 
of the tumours.  
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As a proof-of-concept, we have incubated urine proteins from each group with MNP 
functionalized with three broad spectra lectins: i) ConA, targeting α-linked mannose 
present in N-glycan core oligosaccharides; ii) WGA, targeting terminal GlcNAc units 
common to many glycans found in membrane proteins; iii) SNA, targeting preferentially 
O-6 linked and, to less extent, O-3 linked sialic acids. Proteins showing affinity for these 
lectins were recovered from the beads and identified based on a bottom-up shotgun 
proteomics by nanoLC-MALDI-TOF/TOF. The resulting data was sorted for membrane or 
secreted glycoproteins showing putative N- and/or O-glycosylation sites, based on 
bioinformatics predictions using UniProt, NetNGlyc and NetOGlyc, respectively.  
Overall, we have identified 114 glycoproteins, 63 of which were exclusively found in 
cancer patients’ urines and 21 solely in the controls (Table S1 and S2-Supporting 
Information). Amongst bladder cancer patient urine samples, commonly observed proteins 
were apolipoprotein family members (APOA1, APOE), fibrinogen chains (FGA, FGB, 
FGG), alpha-1-antitrypsin (SERPINA1) and alpha-2-macroglobulin (A2M) (Table 1S-
Supporting Information). A higher number of proteins were identified in high-grade 
NMIBC (n=80) and MIBC (n=96) in comparison to low-grade NMIBC (n=52) and control 
urines (n=55), considering all three lectins and accounting the repetitive capture of some 
proteins by the three lectins (Figure 1A). Nevertheless, cancer-specific glycoproteins 
could be observed in all cancer groups, including low-grade tumours (Figure 1B). 
Moreover, supporting the alterations observed in the glycome, slot-blot analysis of 
individual samples demonstrated that all three lectins presented higher affinity for proteins 
isolated from high-grade lesions, particularly in patients facing muscle-invasion, when 
compared to the controls (Figure S2-Supporting Information). Taken together, these 
findings suggest the existence of significant alterations in the nature of urine glycome and 
glycoproteome, accompanying the transition from low-grade to high-grade lesions; 
however, these alterations become more pronounced upon muscle invasion. 
Considering cancer-associated glycoproteins, 8 protein species were exclusively found in 
low-grade tumours, suggesting potential for early diagnosis of patients with superficial 
lesions. Conversely, 13 were exclusively found in high-grade NMIBC and may aid non-
invasive detection of progression of low-grade lesions. Moreover, 19 glycoproteins have 
been exclusively found in MIBC, holding potential to determine further progression to 
invasion. On the other hand, 12 glycoproteins have been detected in all groups and lack 
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potential for patient discrimination (Figure 2 and Table S2-Supporting Information). We 
have then comprehensively matched these findings against previous reports in bladder 
cancer tissues using Oncomine considering “p=0.001, 2-fold upregulation, All rank” 
thresholds. Interestingly, 81% of the cancer-associated urine glycoproteins had been 
previously detected in both healthy human urothelium and bladder cancer tissues (Figure 2 
and Table S2-Supporting Information). It is possible that the net loss of integrity of the 
urothelium accompanying malignant transformations may ultimately dictate their release 
into urine in pathological situations. Moreover, many of these glycoproteins may 
experience glycome remodeling, favoring affinity for the lectins chosen for enrichment. 
Moreover, 19% of these glycoproteins have been found overexpressed in cancer tissues 
(IGHG3, SERPINA1, CD44, IGHM, HSPG2, GGH, APOE, MUC16, ATP13A2, ADCK2, 
PRSS2, and LAMA5) (Figure 2). More importantly, we note that SERPINA1, IGHM and 
CD44, which are significantly overexpressed in MIBC (according to Oncomine), can be 
detected in the urine of both high-grade NMIBC as well as MIBC patients. These 
observations suggest that these proteins may further aid on non-invasive differentiation 
between low-grade and high-grade tumours and ultimately be useful in risk stratification. 
In accordance, literature demonstrated that SERPINA1 is frequently found in higher stage 
and grade patients and was associated with tumour progression and shorter disease-free 
survival in both urines and tumour tissues from bladder cancer patient’s analysis [24, 25]. 
Regarding IGHM, this is the first report of this protein in bladder cancer as a non-invasive 
differentiator between low-grade and high-grade tumours. Conversely, CD44 has been 
frequently reported as a bladder cancer stem-cell biomarker expressed by more aggressive 
subpopulations [13, 26]. Previous studies have demonstrated the presence of CD44 in 
exfoliated cancer cells in urine and its potential as a urinary marker for bladder cancer 
detection [27, 28]. This is the first report identifying CD44 as a protein that can be released 
into urine and suggesting its potential as a non-invasive stratification marker between low 
and high-grade bladder tumours.  
A comprehensive integration of cancer-associated urine glycobiomarkers using 
Cytoscape’s ClueGo and Cluepedia plugins further demonstrated an overrepresentation of 
MIBC-associated pathways, including regulation of immune responses (humoral and 
complement), platelet degranulation, which has been considered a key event for tumour 
growth and metastasis [29], and cholesterol transport, which may play a critical role in 
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cancer progression [30]. However, there are also common biological features to both 
NMIBC and MIBC, concerning the promotion of heterotypic regulation of cell-cell 
adhesion, mostly mediated by CD44. Given the key role played by CD44, its presence in 
urine samples and overexpression in more aggressive and invasive bladder tumours 
(Oncomine), further emphasis was devoted to validate these results and its potential 
biomarker value in the context of advanced disease.  
 
CD44 expression in urine and bladder tumours 
Orthogonal validation of CD44 expression in urine samples was performed by slot 
blotting. According to Figure 4A, CD44 urinary levels showed a trend increase with the 
severity of the lesions; however, this effect is only significant for high-grade tumours in 
comparison to controls and low-grade NMIBC.  
In parallel, we have screened the corresponding bladder tissues for CD44 expression by 
immunohistochemistry. CD44 antigen was mainly found at the cancer cells membrane, in 
accordance with expected cellular location. Again, we observed a significant 
overexpression of CD44 with the severity of the lesions, which is more pronounced for 
high-grade tumours, thus, mimicking urine analysis. More importantly, CD44 was not 
observed in the tumour-adjacent histologically normal urothelium of the one case with 
normal urothelium representation, neither in the most superficial lesions, supporting its 
overexpression in cancer. In superficial tumours, CD44 was predominantly found in basal 
layer cells, which have been described to harbor more malignant clones. Contrastingly, 
MIBC cells presented an extensive and intense CD44 staining without a defined pattern 
throughout the tumour.  
These findings agree with MNP@ lectins-based glycoproteomics and reinforce the role of 
CD44 in the context of advanced disease (high-grade NMIBC and MIBC). 
 
Discussion and concluding remarks 
The establishment of proteomics workflows to address clinically relevant urine 
glycoproteins in bladder cancer remains challenging due to the lack of efficient enrichment 
strategies. Herein, we have explored the potential of targeting glycans using MNP@lectins 
and/or MNP@moAbs. Nevertheless, we have previously demonstrated that MNP@lectins 
significantly increase glycoprotein yields when compared to conventional immobilization 
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strategies (sepharose/agarose) and microspheres [15]. This is most likely associated to 
superior dynamics provided by large surface volume ratios, while displaying low 
unspecific binding. Moreover, we have used this approach to address the serum, saliva, and 
urine glycoproteomes, which resulted in the identification of proteins spanning large 
dynamic ranges, including low abundant species [16]. Likewise, we have hypothesized that 
this approach could be ideal for addressing cancer-biomarkers, generally present in minute 
amounts (nano-fentomolar range) in urine samples. Accordingly, we have combined 
information from MNP functionalized with three large spectra lectins (ConA - N-glycans 
structures; WGA - GlcNAc in N- and O-glycans; and SNA - sialic acids also present in in 
N- and O-glycans) envisaging biomarker panels associated with different aspects of the 
disease.  
Even though explorative, this study has highlighted significant alterations in the urine 
glycome and glycoproteome, warranting comprehensive and more in-depth evaluation in 
future studies. These changes were significantly more pronounced in MIBC in comparison 
to initial stages of the disease and healthy controls, supporting a disease-associated nature 
of these findings. Amongst the identified proteins were known bladder cancer-associated 
biomarkers apolipoprotein family, fibrinogen chains, alpha-1-antitrypsin, alpha-2-
macroglobulin and uromodulin, previously reported as urinary biomarkers for bladder 
cancer [31, 32]. However, it has been extensively discussed that, individually, these 
proteins lack the necessary sensitivity and specificity to face the main clinical challenges 
raised by bladder cancer management, i.e. early identification of patients facing disease 
progression to high-grade disease and invasion. Giving this challenge, our strategy has 
generated a broader panel of 42 glycoproteins associated to high-grade disease (NMIBC 
and MIBC) that may hold clinical potential, 19 of which exclusively found in MIBC. In 
addition, the comprehensive integration of data using protein-protein interaction networks 
(Cytoscape) demonstrated the existence of common pathways to both NMIBC and MIBC 
(humoral response, complement activation, cell-adhesion) even though driven by different 
protein players. Amongst these glycoproteins is CD44, which has been found to modulate 
cell-cell adhesion in both NMIBC and MIBC (oncomine) and has been previously reported 
to drive invasion and metastasis [33, 34]. In agreement with these observations, we found 
high levels of CD44 in the urine of patients diagnosed with high-grade NMIBC and MIBC, 
possibly reflecting the molecular nature of the tumour. The CD44 antigen has been 
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previously found overexpressed in more aggressive bladder tumours and bladder cancer 
cells exfoliated into urine, and is frequently associated to poor prognosis [27]. 
Nevertheless, this is the first report demonstrating the shedding of this glycoprotein into 
urine, supporting its potential as biomarkers of disease progression. However, CD44 may 
present several isoforms that may change according to the origin of the tumour as well as 
the severity of the lesions. In bladder cancer, the most described CD44 isoforms are 
CD44s, CD44v6 and CD44v9, both associated with poor prognosis [35-37]. Variations in 
CD44 expression might be connected to the derangement of differentiation in bladder 
tumour cells [38]. Moreover, these cells are usually located in the basal layer of normal 
urothelium, the potential location of initiation tumour bladder cells, thereby reinforcing the 
value of CD44 as bladder cancer stem cell marker [39]. 
 Future studies should therefore devote to a comprehensive clarification of the 
nature of CD44 isoforms patterns as well as its glycoforms in bladder cancer envisaging 
highly specific biomarkers. The identification of clinically relevant CD44 glycoforms may 
further enhance the biomarker value of this glycoprotein, has previously demonstrated for 
other glycoproteins, namely PSA in prostate cancer [40]. Accordingly, we believe that the 
MNP@lectins-based enrichment strategy may also constitute a key starting point for 
glycome characterization by narrowing down identified glycoproteins to its clinically 
relevant glycoforms.  
In summary, we believe that the future of biomarker discovery in bladder cancer should 
include a comprehensive interrogation of the glycome and glycoproteome, as well as the 
integration of relevant glycobiomarkers into broader panomics data. The generalization of 
glycan-based enrichment nanoplatforms may provide the necessary means to achieve this 
goal. 
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Figures 
 
 
 
Figure 1. Urine glycoproteins identified in controls and low-grade NMIBC, high-
grade NMIBC and MIBC using MNP@ConA, MNP@WGA and MNP@SNA lectins. 
A. A higher number of proteins were identified for high-grade NMIBC (n=80) and MIBC 
(n=96) in comparison to low-grade NMIBC (n=52) and control urines (n=55), considering 
all three lectins. B. Venn diagram highlighting the existence of distinct lectin-based 
glycoprotein signatures for each group, holding potential for early detection (low-grade 
tumours group); disease progression to undifferentiating (high-grade NMIBC group); 
progression to invasion (MIBC) and poor prognosis (high-grade NMIBC+MIBC group).  
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Figure 2. Graphical representation of cancer-specific urine glycobiomarkers with 
affinity to MNP@ConA, MNP@WGA and MNP@SNA lectin nanoprobes distributed 
according to their expression in bladder cancer. Accordingly 63 glycoproteins were 
exclusively found in cancer samples, (top right Venn diagram). The left panel represents 
the distribution of these glycoproteins amongst the cancer groups (low-grade and high-
grade NMIBC and MIBC). Significant associations of these glycoproteins with different 
aspects of the disease according to an in silico analysis with Oncomine was represented by 
different protein name colours. The number of predicted O- and N-glycosylation sites were 
also represented according to results from NetOGlyc and NetNGlyc bioinformatics tools, 
respectively. 
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Figure 3. Network presenting the most significant biological functions of the 
candidate glycobiomarkers in bladder cancer. This network mainly reflects biological 
functions of immune system regulation (humoral response and complement), platelet 
degranulation and cholesterol transport as also heterotypic cell-cell adhesion, which is 
essentially played by CD44 glycoprotein in both NMIBC and MIBC. 
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Figure 4. Validation of CD44 expression in urine samples and immunohistochemistry 
of bladder cancer patients. A. CD44 urinary levels showed a trend increase with the 
severity of the lesions; however this effect is only significant for high-grade tumours in 
comparison to the control and low-grade NMIBC groups. B. CD44 antigen was mainly 
found at membrane of cancer cells, in accordance with expected cellular location. Again, 
we observed a significant overexpression of CD44 with the severity of the lesions, which is 
more pronounced for high-grade tumours, thus, mimicking urine analyses. C. In superficial 
tumours, CD44 was predominantly found in cells underlining the basal layer, which have 
been described to harbor more malignant clones. Contrastingly, MIBC cells presented an 
extensive and intense CD44 expression without a defined pattern throughout the tumour. * 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
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Figure S1. Protein content and total sialic acids of urines from controls and bladder 
cancer patients with low-grade NMIBC, high-grade NMIBC and MIBC. A significant 
increase in urinary proteinuria and in sialic acids content was observed along with the 
severity of the bladder cancer lesions in comparison to individuals without known 
neoplasia, matched in age and gender.  
* p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001 
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Table S1. Extracellular membrane-bound or secreted glycoproteins with affinity to ConA, WGA or SNA 
lectins showing N- or O-glycosylation that were identified in urine samples from controls 
Protein Name MW Entry N-glycosylated O-glycosylated ConA WGA SNA 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 PE=1 
SV=1 23 P02763 YES NO 
  
√ 
Alpha-2-HS-glycoprotein OS=Homo 
sapiens GN=AHSG PE=1 SV=1 39 P02765 YES YES 
  
√ 
Alpha-2-macroglobulin-like protein 1 
OS=Homo sapiens GN=A2ML1 PE=1 
SV=2 161 A8K2U0 YES YES 
  
√ 
Alpha-amylase 2B OS=Homo sapiens 
GN=AMY2B PE=1 SV=1 58 P19961 YES YES 
  
√ 
Apolipoprotein B-100 OS=Homo 
sapiens GN=APOB PE=1 SV=1 515 P04114 YES YES 
  
√ 
Cerebellin-2 OS=Homo sapiens 
GN=CBLN2 PE=2 SV=1 24 Q8IUK8 YES YES 
 
√ 
 Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 122 P00450 YES YES 
  
√ 
Desmoglein-1 OS=Homo sapiens 
GN=DSG1 PE=1 SV=2 114 Q02413 YES YES √ 
  Dipeptidase 2 OS=Homo sapiens 
GN=DPEP2 PE=1 SV=1 53 Q9H4A9 YES YES 
 
√ 
 Fibrocystin-L OS=Homo sapiens 
GN=PKHD1L1 PE=2 SV=2 465 Q86WI1 YES YES √ 
  Fibronectin OS=Homo sapiens 
GN=FN1 PE=1 SV=3 262 P02751 YES YES 
  
√ 
Frizzled-4 OS=Homo sapiens 
GN=FZD4 PE=1 SV=2 60 Q9ULV1 YES YES 
 
√ 
 Galectin-3-binding protein OS=Homo 
sapiens GN=LGALS3BP PE=1 SV=1 65 Q08380 YES YES 
  
√ 
Gamma-interferon-inducible 
lysosomal thiol reductase OS=Homo 
sapiens GN=IFI30 PE=1 SV=2 29 P13284 YES NO 
  
√ 
G-protein coupled receptor 98 
OS=Homo sapiens GN=GPR98 PE=1 
SV=1 692 Q8WXG9 YES YES 
  
√ 
Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2 38 P01876 YES YES 
  
√ 
Ig gamma-2 chain C region OS=Homo 
sapiens GN=IGHG2 PE=1 SV=2 36 P01859 YES YES 
  
√ 
Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 12 P01834 NO YES 
  
√ 
Immunoglobulin superfamily member 
10 OS=Homo sapiens GN=IGSF10 
PE=1 SV=1 291 Q6WRI0 YES YES 
  
√ 
Indian hedgehog protein OS=Homo 
sapiens GN=IHH PE=1 SV=4 45 Q14623 YES YES 
 
√ 
 Integrin alpha-L OS=Homo sapiens 
GN=ITGAL PE=1 SV=3 129 P20701 YES YES 
 
√ 
 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens 
GN=ITIH4 PE=1 SV=4 103 Q14624 YES YES 
  
√ 
Interleukin-17 receptor A OS=Homo 
sapiens GN=IL17RA PE=1 SV=2 96 Q96F46 YES YES 
 
√ 
 Junction plakoglobin OS=Homo 
sapiens GN=JUP PE=1 SV=3 82 P14923 YES YES √ 
  Laminin subunit alpha-2 OS=Homo 
sapiens GN=LAMA2 PE=1 SV=4 344 P24043 YES YES √ √ 
 Large proline-rich protein BAT3 
OS=Homo sapiens GN=BAT3 PE=1 
SV=2 119 P46379 YES YES √ √ 
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Lutropin-choriogonadotropic hormone 
receptor OS=Homo sapiens 
GN=LHCGR PE=1 SV=4 79 P22888 YES YES 
 
√ 
 Macrophage-stimulating protein 
receptor OS=Homo sapiens 
GN=MST1R PE=1 SV=1 152 Q04912 YES YES √ 
  Monocyte differentiation antigen 
CD14 OS=Homo sapiens GN=CD14 
PE=1 SV=2 40 P08571 YES YES 
  
√ 
Neurotensin receptor type 2 OS=Homo 
sapiens GN=NTSR2 PE=2 SV=1 45 O95665 NO YES 
 
√ 
 Osteopontin OS=Homo sapiens 
GN=SPP1 PE=1 SV=1 35 P10451 YES YES 
 
√ 
 Otoferlin OS=Homo sapiens 
GN=OTOF PE=1 SV=3 227 Q9HC10 YES YES 
 
√ 
 Pancreatic alpha-amylase OS=Homo 
sapiens GN=AMY2A PE=1 SV=2 58 P04746 YES YES 
  
√ 
Pepsin A OS=Homo sapiens 
GN=PGA3 PE=1 SV=1 42 P0DJD8 NO YES 
  
√ 
Plasma serine protease inhibitor 
OS=Homo sapiens GN=SERPINA5 
PE=1 SV=2 46 P05154 YES YES 
  
√ 
Prostaglandin-H2 D-isomerase 
OS=Homo sapiens GN=PTGDS PE=1 
SV=1 21 P41222 YES NO 
  
√ 
Protein AMBP OS=Homo sapiens 
GN=AMBP PE=1 SV=1 39 P02760 YES YES 
  
√ 
Protein notum homolog OS=Homo 
sapiens GN=NOTUM PE=2 SV=2 56 Q6P988 YES YES 
 
√ 
 Protocadherin Fat 1 OS=Homo sapiens 
GN=FAT1 PE=1 SV=1 506 Q14517 YES YES √ 
  Protocadherin Fat 2 OS=Homo sapiens 
GN=FAT2 PE=1 SV=1 479 Q9NYQ8 YES YES √ 
  Putative maltase-glucoamylase-like 
protein FLJ16351 OS=Homo sapiens 
PE=2 SV=1 74 Q2M2H8 YES YES 
  
√ 
Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=2 77 P02787 YES YES 
  
√ 
Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 69 P02768 NO YES 
  
√ 
Tenascin-X OS=Homo sapiens 
GN=TNXB PE=1 SV=3 464 P22105 YES YES 
 
√ 
 Transmembrane protein 132D 
OS=Homo sapiens GN=TMEM132D 
PE=2 SV=1 122 Q14C87 YES YES √ 
  Transmembrane protein 214 
OS=Homo sapiens GN=TMEM214 
PE=1 SV=2 77 Q6NUQ4 YES YES 
 
√ 
 Transmembrane protein 8A OS=Homo 
sapiens GN=TMEM8A PE=1 SV=2 85 Q9HCN3 YES YES 
 
√ 
 Uromodulin OS=Homo sapiens 
GN=UMOD PE=1 SV=1 70 P07911 YES YES √ 
 
√ 
Vesicle-associated membrane protein 5 
OS=Homo sapiens GN=VAMP5 PE=1 
SV=1 13 O95183 YES YES 
 
√ 
 WAP, kazal, immunoglobulin, kunitz 
and NTR domain-containing protein 2 
OS=Homo sapiens GN=WFIKKN2 P 64 Q8TEU8 YES YES √ √ 
 Zinc-alpha-2-glycoprotein OS=Homo 
sapiens GN=AZGP1 PE=1 SV=2 34 P25311 YES YES 
  
√ 
 
Table S2. Cancer-specific extracellular membrane-bound or secreted glycoproteins with affinity to ConA, WGA or SNA 
lectins showing N- or O-glycosylation that were identified in urine samples from bladder cancer patients 
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Protein Name MW Entry 
O-glycosylation 
sites  
N-glycosylation 
sites Bladder cancer ConA WGA SNA Oncomine 
Alpha-2-macroglobulin 
OS=Homo sapiens 
GN=A2M PE=1 SV=2 163 P01023 4 8 All √ √ √ NS 
Fibrinogen beta chain 
OS=Homo sapiens 
GN=FGB PE=1 SV=2 56 P02675 5 1 All √ √ √ NS 
Complement C3 
OS=Homo sapiens 
GN=C3 PE=1 SV=2 187 P01024 >10 2 All 
 
√ √ NS 
Fibrinogen gamma 
chain OS=Homo 
sapiens GN=FGG PE=1 
SV=3 51 P02679 4 1 All 
 
√ √ NS 
Pregnancy zone protein 
OS=Homo sapiens 
GN=PZP PE=1 SV=4 164 P20742 8 >10 All 
 
√ √ NS 
Apolipoprotein A-I 
OS=Homo sapiens 
GN=APOA1 PE=1 
SV=1 31 P02647 4 NO All √ √ √ NS 
Complement C4-B 
OS=Homo sapiens 
GN=C4B PE=1 SV=1 193 P0C0L5 >10 5 All 
  
√ NS 
Ig gamma-1 chain C 
region OS=Homo 
sapiens GN=IGHG1 
PE=1 SV=1 36 P01857 7 1 All √ √ √ NS 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 
SV=1 45 P00738 5 4 All √ √ √ NS 
Ig gamma-3 chain C 
region OS=Homo 
sapiens GN=IGHG3 
PE=1 SV=2 41 P01860 >10 1 All √ √ √ MIBC 
Fibrinogen alpha chain 
OS=Homo sapiens 
GN=FGA PE=1 SV=2 95 P02671 >10 2 All 
 
√ √ NS 
Pecanex-like protein 1 
OS=Homo sapiens 
GN=PCNX PE=2 SV=2 259 Q96RV3 >10 7 All 
 
√ √ NS 
Leucine-rich alpha-2-
glycoprotein OS=Homo 
sapiens GN=LRG1 
PE=1 SV=2 38 P02750 5 2 
HG 
NMIBC/MIBC √ √ 
 
NS 
Alpha-1-antitrypsin 
OS=Homo sapiens 
GN=SERPINA1 PE=1 
SV=3 47 P01009 5 4 
HG 
NMIBC/MIBC 
 
√ √ MIBC 
CD44 antigen 
OS=Homo sapiens 
GN=CD44 PE=1 SV=2 82 P16070 >10 8 
HG 
NMIBC/MIBC 
 
√ 
 
MIBC 
Complement C5 
OS=Homo sapiens 
GN=C5 PE=1 SV=4 188 P01031 8 3 
HG 
NMIBC/MIBC 
 
√ √ NS 
Hemopexin OS=Homo 
sapiens GN=HPX PE=1 
SV=2 52 P02790 9 5 
HG 
NMIBC/MIBC 
 
√ √ NS 
Kininogen-1 OS=Homo 
sapiens GN=KNG1 
PE=1 SV=2 72 P01042 >10 3 
HG 
NMIBC/MIBC 
 
√ √ NS 
Vitronectin OS=Homo 
sapiens GN=VTN PE=1 54 P04004 >10 2 
HG 
NMIBC/MIBC 
 
√ √ NS 
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SV=1 
Ig mu heavy chain 
disease protein 
OS=Homo sapiens 
PE=1 SV=1 43 P01871 2 5 
HG 
NMIBC/MIBC 
  
√ MIBC 
Basement membrane-
specific heparan sulfate 
proteoglycan core 
protein OS=Homo 
sapiens GN=HSPG2 
PE=1 SV=3 469 P98160 >10 8 
HG 
NMIBC/MIBC 
 
√ √ NMIBC 
SCO-spondin 
OS=Homo sapiens 
GN=SSPO PE=2 SV=1 547 A2VEC9 >10 >10 
HG 
NMIBC/MIBC 
  
√ NS 
Ig gamma-4 chain C 
region OS=Homo 
sapiens GN=IGHG4 
PE=1 SV=1 36 P01861 9 1 MIBC √ 
 
√ No results 
Ig lambda chain C 
regions OS=Homo 
sapiens GN=IGLC1 
PE=1 SV=1 11 P0CG04 3 1 MIBC √ 
 
√ No results 
Prostatic acid 
phosphatase OS=Homo 
sapiens GN=ACPP 
PE=1 SV=3 45 P15309 6 3 MIBC √ 
  
NS 
Mannan-binding lectin 
serine protease 2 
OS=Homo sapiens 
GN=MASP2 PE=1 
SV=3 76 O00187 >10 NO MIBC √ 
  
NS 
Transthyretin 
OS=Homo sapiens 
GN=TTR PE=1 SV=1 16 P02766 1 NO MIBC √ 
  
NS 
Gamma-glutamyl 
hydrolase OS=Homo 
sapiens GN=GGH 
PE=1 SV=2 36 Q92820 NO 3 MIBC √ 
  
Both 
Complement factor H 
OS=Homo sapiens 
GN=CFH PE=1 SV=4 139 P08603 >10 4 MIBC 
 
√ √ NS 
Haptoglobin-related 
protein OS=Homo 
sapiens GN=HPR PE=1 
SV=2 39 P00739 2 3 MIBC 
  
√ NS 
Keratin, type II 
cytoskeletal 1 
OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 66 P04264 >10 2 MIBC 
  
√ NS 
Alpha-1B-glycoprotein 
OS=Homo sapiens 
GN=A1BG PE=1 SV=3 54 P04217 1 4 MIBC 
  
√ NS 
Alpha-1-
antichymotrypsin 
OS=Homo sapiens 
GN=SERPINA3 PE=1 
SV=2 48 P01011 2 4 MIBC 
  
√ NS 
Plasminogen OS=Homo 
sapiens GN=PLG PE=1 
SV=2 91 P00747 >10 NO MIBC 
  
√ NS 
Serum amyloid A 
protein OS=Homo 
sapiens GN=SAA1 
PE=1 SV=2 14 P0DJI8 1 NO MIBC 
  
√ NS 
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Apolipoprotein E 
OS=Homo sapiens 
GN=APOE PE=1 SV=1 36 P02649 10 NO MIBC 
  
√ MIBC 
Clusterin OS=Homo 
sapiens GN=CLU PE=1 
SV=1 52 P10909 5 6 MIBC 
  
√ NS 
von Willebrand factor 
A domain-containing 
protein 5B1 OS=Homo 
sapiens GN=VWA5B1 
PE=1 SV=2 134 Q5TIE3 >10 5 MIBC 
  
√ NS 
Zonadhesin OS=Homo 
sapiens GN=ZAN PE=2 
SV=3 305 Q9Y493 >10 10 MIBC 
  
√ NS 
IgGFc-binding protein 
OS=Homo sapiens 
GN=FCGBP PE=1 
SV=3 572 Q9Y6R7 >10 >10 MIBC 
  
√ NS 
Collagen alpha-3(IV) 
chain OS=Homo 
sapiens GN=COL4A3 
PE=1 SV=3 162 Q01955 >10 1 MIBC 
  
√ NS 
Sodium channel protein 
type 2 subunit alpha 
OS=Homo sapiens 
GN=SCN2A PE=1 
SV=3 228 Q99250 >10 >10 LG NMIBC √ 
  
NS 
Mucin-16 OS=Homo 
sapiens GN=MUC16 
PE=1 SV=2 3007 Q8WXI7 >10 >10 LG/HG NMIBC √ 
 
√ MIBC 
Probable cation-
transporting ATPase 
13A2 OS=Homo 
sapiens GN=ATP13A2 
PE=2 SV=2 129 Q9NQ11 6 2 LG NMIBC √ 
  
Both 
Pyridoxal phosphate 
phosphatase OS=Homo 
sapiens GN=PDXP 
PE=1 SV=2 32 Q96GD0 NO 2 LG NMIBC √ 
  
NS 
Uncharacterized aarF 
domain-containing 
protein kinase 2 
OS=Homo sapiens 
GN=ADCK2 PE=2 
SV=1 69 Q7Z695 6 NO LG NMIBC √ 
  
NMIBC 
Down syndrome cell 
adhesion molecule-like 
protein 1 OS=Homo 
sapiens 
GN=DSCAML1 PE=1 
SV=2 224 Q8TD84 >10 >10 LG NMIBC 
 
√ 
 
NS 
Protein kinase C-
binding protein NELL2 
OS=Homo sapiens 
GN=NELL2 PE=1 
SV=1 91 Q99435 >10 7 LG NMIBC 
 
√ 
 
NS 
Protein patched 
homolog 2 OS=Homo 
sapiens GN=PTCH2 
PE=2 SV=2 130 Q9Y6C5 >10 3 LG NMIBC 
 
√ 
 
NS 
Zymogen granule 
protein 16 homolog B 
OS=Homo sapiens 
GN=ZG16B PE=1 23 Q96DA0 5 1 LG NMIBC 
  
√ NS 
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SV=3 
Trypsin-2 OS=Homo 
sapiens GN=PRSS2 
PE=1 SV=1 26 P07478 1 NO HG NMIBC √ 
  
MIBC 
Ig alpha-2 chain C 
region OS=Homo 
sapiens GN=IGHA2 
PE=1 SV=3 37 P01877 6 5 HG NMIBC √ 
  
No results 
Collagen alpha-1(XX) 
chain OS=Homo 
sapiens GN=COL20A1 
PE=1 SV=4 136 Q9P218 >10 1 HG NMIBC √ 
  
NS 
Probable phospholipid-
transporting ATPase 
IIB OS=Homo sapiens 
GN=ATP9B PE=2 
SV=4 129 O43861 10 1 HG NMIBC √ 
  
NS 
Epidermal growth 
factor receptor substrate 
15-like 1 OS=Homo 
sapiens GN=EPS15L1 
PE=1 SV=1 94 Q9UBC2 >10 4 HG NMIBC √ 
  
NS 
Olfactory receptor 11L1 
OS=Homo sapiens 
GN=OR11L1 PE=2 
SV=1 37 Q8NGX0 NO 1 HG NMIBC √ 
  
NS 
Laminin subunit alpha-
1 OS=Homo sapiens 
GN=LAMA1 PE=1 
SV=2 337 P25391 >10 >10 HG NMIBC √ 
  
NS 
Potassium voltage-
gated channel subfamily 
H member 7 OS=Homo 
sapiens GN=KCNH7 
PE=1 SV=2 135 Q9NS40 >10 8 HG NMIBC √ 
  
NS 
Vasorin OS=Homo 
sapiens GN=VASN 
PE=1 SV=1 72 Q6EMK4 >10 5 HG NMIBC 
 
√ 
 
NS 
Histidine-rich 
glycoprotein OS=Homo 
sapiens GN=HRG PE=1 
SV=1 60 P04196 >10 3 HG NMIBC 
  
√ NS 
Laminin subunit alpha-
5 OS=Homo sapiens 
GN=LAMA5 PE=1 
SV=7 400 O15230 >10 >10 HG NMIBC 
  
√ NMIBC 
Sphingosine 1-
phosphate receptor 5 
OS=Homo sapiens 
GN=S1PR5 PE=2 
SV=1 42 Q9H228 >10 1 HG NMIBC 
  
√ NS 
Transmembrane protein 
131 OS=Homo sapiens 
GN=TMEM131 PE=1 
SV=2 201 Q92545 >10 >10 HG NMIBC 
  
√ NS 
NS: not significantly associated. In Oncomine: threshold: p=0.001, 2-fold, All rank. 
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Figure S2. Slot-blot analysis of urine samples using the ConA, WGA and SNA lectins. 
Slot-blot analysis of individual samples demonstrated that all three lectins presented higher 
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affinity for proteins isolated from high-grade lesions, in particular in patients facing 
muscle-invasion, when compared to the controls. 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
 
